<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">90695</article-id><article-id pub-id-type="doi">10.7554/eLife.90695</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.90695.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Human-induced pluripotent stem cell-derived microglia integrate into mouse retina and recapitulate features of endogenous microglia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Wenxin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8396-6625</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Lian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Biying</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8608-6797</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Fariss</surname><given-names>Robert N</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Redmond</surname><given-names>T Michael</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Jizhong</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wong</surname><given-names>Wai T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0681-4016</contrib-id><email>Wai@tiresiasbio.com</email><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Wei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2897-649X</contrib-id><email>liwei2@nei.nih.gov</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wkg3b53</institution-id><institution>Retinal Neurophysiology Section, National Eye Institute</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wkg3b53</institution-id><institution>Genetic Engineering Core, National Eye Institute</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wkg3b53</institution-id><institution>Immunoregulation Section, National Eye Institute</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wkg3b53</institution-id><institution>Biological Imaging Core, National Eye Institute</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wkg3b53</institution-id><institution>Molecular Mechanisms Section, National Eye Institute</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>iPSC Core, National Heart, Lung, and Blood Institute</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Tiresias Bio</institution><addr-line><named-content content-type="city">Half Moon Bay</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Xiaorong</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0153tk833</institution-id><institution>University of Virginia</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Smith</surname><given-names>Lois EH</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00dvg7y05</institution-id><institution>Boston Children's Hospital</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>11</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP90695</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-07-05"><day>05</day><month>07</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-08-02"><day>02</day><month>08</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.07.31.550858"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-08-22"><day>22</day><month>08</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.90695.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-07-15"><day>15</day><month>07</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.90695.2"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-90695-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-90695-figures-v1.pdf"/><related-article related-article-type="commentary" ext-link-type="doi" xlink:href="10.7554/eLife.103535" id="ra1"/><abstract><p>Microglia exhibit both maladaptive and adaptive roles in the pathogenesis of neurodegenerative diseases and have emerged as a cellular target for central nervous system (CNS) disorders, including those affecting the retina. Replacing maladaptive microglia, such as those impacted by aging or over-activation, with exogenous microglia that can enable adaptive functions has been proposed as a potential therapeutic strategy for neurodegenerative diseases. To investigate microglia replacement as an approach for retinal diseases, we first employed a protocol to efficiently generate human-induced pluripotent stem cell (hiPSC)-derived microglia in quantities sufficient for in vivo transplantation. These cells demonstrated expression of microglia-enriched genes and showed typical microglial functions such as LPS-induced responses and phagocytosis. We then performed xenotransplantation of these hiPSC-derived microglia into the subretinal space of adult mice whose endogenous retinal microglia have been pharmacologically depleted. Long-term analysis post-transplantation demonstrated that transplanted hiPSC-derived microglia successfully integrated into the neuroretina as ramified cells, occupying positions previously filled by the endogenous microglia and expressed microglia homeostatic markers such as P2ry12 and Tmem119. Furthermore, these cells were found juxtaposed alongside residual endogenous murine microglia for up to 8 months in the retina, indicating their ability to establish a stable homeostatic state in vivo. Following retinal pigment epithelial cell injury, transplanted microglia demonstrated responses typical of endogenous microglia, including migration, proliferation, and phagocytosis. Our findings indicate the feasibility of microglial transplantation and integration in the retina and suggest that modulating microglia through replacement may be a therapeutic strategy for treating neurodegenerative retinal diseases.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>human iPSC</kwd><kwd>microglia</kwd><kwd>PLX-5622</kwd><kwd>retinal transplantation</kwd><kwd>RPE</kwd><kwd>NaIO<sub>3</sub></kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ma</surname><given-names>Wenxin</given-names></name><name><surname>Zhao</surname><given-names>Lian</given-names></name><name><surname>Xu</surname><given-names>Biying</given-names></name><name><surname>Fariss</surname><given-names>Robert N</given-names></name><name><surname>Redmond</surname><given-names>T Michael</given-names></name><name><surname>Zou</surname><given-names>Jizhong</given-names></name><name><surname>Wong</surname><given-names>Wai T</given-names></name><name><surname>Li</surname><given-names>Wei</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Transplanted human iPSC-derived microglial cells with immune responses and phagocytic abilities integrate and occupy native microglial cell space and functionally respond to retinal injuries.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Microglia are the innate immune cells of the central nervous system (CNS), including the retina, and play pivotal roles in neuronal (<xref ref-type="bibr" rid="bib61">Puñal et al., 2019</xref>; <xref ref-type="bibr" rid="bib2">Anderson et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Huang et al., 2012</xref>) and vascular development (<xref ref-type="bibr" rid="bib13">Checchin et al., 2006</xref>; <xref ref-type="bibr" rid="bib64">Ritter et al., 2006</xref>; <xref ref-type="bibr" rid="bib39">Kubota et al., 2009</xref>), normal synapse formation (<xref ref-type="bibr" rid="bib72">Stevens et al., 2007</xref>; <xref ref-type="bibr" rid="bib65">Schafer et al., 2012</xref>; <xref ref-type="bibr" rid="bib66">Schafer and Stevens, 2015</xref>; <xref ref-type="bibr" rid="bib34">Hong et al., 2016</xref>), maintaining local homeostasis in the neural environment (<xref ref-type="bibr" rid="bib43">Li and Barres, 2018</xref>; <xref ref-type="bibr" rid="bib14">Colonna and Butovsky, 2017</xref>; <xref ref-type="bibr" rid="bib69">Sierra et al., 2013</xref>), and the regulation of immune activity (<xref ref-type="bibr" rid="bib54">Okunuki et al., 2019</xref>). Conversely, they are also implicated in driving pathologic progression in various retinal diseases, including age-related macular degeneration (AMD) (<xref ref-type="bibr" rid="bib15">Combadière et al., 2007</xref>; <xref ref-type="bibr" rid="bib46">Ma et al., 2009</xref>, <xref ref-type="bibr" rid="bib47">Ma et al., 2012</xref>; <xref ref-type="bibr" rid="bib38">Karlstetter et al., 2015</xref>), glaucoma (<xref ref-type="bibr" rid="bib7">Bosco et al., 2019</xref>; <xref ref-type="bibr" rid="bib62">Ramírez et al., 2020</xref>), diabetic retinopathy (<xref ref-type="bibr" rid="bib84">Xu and Chen, 2017</xref>), and uveitis (<xref ref-type="bibr" rid="bib9">Broderick et al., 2002</xref>; <xref ref-type="bibr" rid="bib54">Okunuki et al., 2019</xref>; <xref ref-type="bibr" rid="bib91">Zhou et al., 2020</xref>).</p><p>Under homeostatic conditions in the adult retina, microglial cells are predominantly distributed in the inner plexiform layer (IPL) and outer plexiform layer (OPL) and vigilantly survey environmental changes through dynamic surveying behavior in their ramified processes (<xref ref-type="bibr" rid="bib42">Lee et al., 2008</xref>). Their presence and homeostatic function are crucial for maintaining normal retinal functions, including the maintenance of synaptic function and integrity (<xref ref-type="bibr" rid="bib81">Wang et al., 2016</xref>). Under normal conditions, microglial cells sustain equilibrium in their endogenous numbers via slow self-renewal (<xref ref-type="bibr" rid="bib63">Réu et al., 2017</xref>). However, with the onset of pathology, this homeostasis can be disrupted following microglia activation, migration, and proliferation. Microglia repopulation in the retina following perturbation is achieved through both the proliferation of endogenous microglia and the infiltration of peripheral monocytes (<xref ref-type="bibr" rid="bib49">Ma et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Huang et al., 2018</xref>; <xref ref-type="bibr" rid="bib87">Zhang et al., 2018</xref>).</p><p>Studies of microglia cell repopulation have indicated that retinal resident microglia can sustain their population with the local microglial cell dividing and migration if any perturbations do not exceed the threshold of the recovery speed by local neighbor microglia. However, in cases of more severe retinal injury or infection that cause significant redistribution of endogenous microglia, the reestablishment of retinal microglial homeostasis will, in addition, involve peripheral monocytes that infiltrate into the retina to take up residence as macrophages. The ability of the retina to incorporate exogenous monocytic cells suggests that microglia cell replacement employing exogenously introduced microglia may be feasible and can exert therapeutic effects post-injury. Inhibiting retinal microglia over-activation has shown efficacy in animal models of retinal injury (<xref ref-type="bibr" rid="bib88">Zhao et al., 2011</xref>; <xref ref-type="bibr" rid="bib38">Karlstetter et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Au and Ma, 2022</xref>) and potential signal in early-phase clinical trials (<xref ref-type="bibr" rid="bib16">Cukras et al., 2012</xref>). These observations suggest that the depletion of maladaptive microglia in pathological contexts and their replacement with microglia that have a more homeostatic phenotype may constitute a potential therapeutic strategy.</p><p>Studies of microglia have largely been performed in rodent-derived models, largely due to the accessibility of various transgenic disease models. However, several studies have indicated that genetic and functional differences exist between murine and human microglia (<xref ref-type="bibr" rid="bib18">Dawson et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Friedman et al., 2018</xref>; <xref ref-type="bibr" rid="bib76">Ueda et al., 2016</xref>). For instance, microglia-expressed genes CD33 and CR1, which have been associated with Alzheimer’s disease (AD) risk in genome-wide association studies, lack reliable orthologs in mice (<xref ref-type="bibr" rid="bib32">Hasselmann and Blurton-Jones, 2020</xref>). Additionally, over half of the AD risk genes that are enriched in microglia demonstrate &lt;70% sequence homology between humans and mice (<xref ref-type="bibr" rid="bib32">Hasselmann and Blurton-Jones, 2020</xref>). There are also significant differences in the levels of protein expression of some microglia-expressed complement factors and inflammatory cytokines between humans and mice (<xref ref-type="bibr" rid="bib25">Galatro et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Gosselin et al., 2017</xref>; <xref ref-type="bibr" rid="bib71">Smith and Dragunow, 2014</xref>). As a result, microglia from murine models may not accurately represent those found in human conditions (<xref ref-type="bibr" rid="bib10">Burns et al., 2015</xref>), limiting their translational potential.</p><p>To study microglia of human origin, some investigators have attempted to isolate microglial cells from human tissue. However, owing to limitations in sample availability, and the rapid transcriptomic changes that ex vivo microglia undergo post-isolation, these studies have been technically constrained (<xref ref-type="bibr" rid="bib6">Bohlen et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Butovsky et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Gosselin et al., 2017</xref>). As an alternative to primary microglia, human-induced pluripotent stem cells (iPSCs) offer a wealth of possibilities and have been increasingly used to generate human microglia via differentiation in vitro (<xref ref-type="bibr" rid="bib51">Muffat et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Pandya et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Douvaras et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Haenseler et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Takata et al., 2017</xref>). This approach has enabled the generation of a large quantity of cells of a specified genetic background, enabling the creation of in vivo human microglia cell models through xenotransplantation of human-induced pluripotent stem cell (hiPSC)-derived microglia into the murine CNS (<xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>; <xref ref-type="bibr" rid="bib73">Svoboda et al., 2019</xref>; <xref ref-type="bibr" rid="bib57">Parajuli et al., 2021</xref>; <xref ref-type="bibr" rid="bib85">Xu et al., 2020a</xref>; <xref ref-type="bibr" rid="bib12">Chadarevian et al., 2023</xref>).</p><p>In this study, we adopted a previously published protocol appropriate for culturing hiPSC-derived microglial cells (<xref ref-type="bibr" rid="bib51">Muffat et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Pandya et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Douvaras et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Haenseler et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Takata et al., 2017</xref>). We characterized microglia differentiation by examining the RNA and protein expression levels of microglia-enriched genes. We also assessed the inflammatory responses and phagocytic functions of hiPSC-derived microglia in vitro. We then established a human iPSC-derived microglia cell model through the xenotransplantation of human iPSC-derived microglial cells into the retina of an adult mouse. We found that when transplanted by subretinal injection, human iPSC-derived microglial cells were able to migrate into the retina where native retinal microglia reside and acquire a morphology resembling endogenous mouse microglia, and express microglia signature markers. These grafted cells persisted in the mouse retina for at least 8 months and responded to retinal pigment epithelial (RPE) cell injury in ways resembling endogenous mouse microglia. Xenografting of hiPSC-derived microglia into mouse retina has the promise of being used to create in vivo models of retinal disease and injury to evaluate the preclinical efficacy of potential therapeutic agents, as well as to evaluate microglia transplantation itself as a potential therapeutic intervention.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Differentiation and characterization of human iPSC-derived microglia</title><p>We used five distinct human iPSC lines for microglia cell differentiation, including the first-available iPSC line, KYOUDXR0109B, from ATCC; and four other lines NCRM6, MS19-ES-H, ND2-AAVS1-iCAG-tdTomato, and NCRM5-AAVS1-CAG-EGFP, from the National Heart, Lung, and Blood Institute (NHLBI). Our approach to microglia differentiation was informed by our previous work with primary mouse retinal microglia cell culture (<xref ref-type="bibr" rid="bib46">Ma et al., 2009</xref>) and a variety of established microglia cell differentiation protocols (<xref ref-type="bibr" rid="bib51">Muffat et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Pandya et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Douvaras et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Haenseler et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Takata et al., 2017</xref>). We opted for the myeloid progenitor/microglia cell floating culture method (<xref ref-type="bibr" rid="bib79">van Wilgenburg et al., 2013</xref>; <xref ref-type="bibr" rid="bib30">Haenseler et al., 2017</xref>) for its simplicity, efficiency, and consistency, which enables the generation of a large and uniform population of microglial cells.</p><p>The differentiation process involved three key stages: embryoid body (EB) formation, myeloid progenitor cell generation, and microglia cell maturation (<xref ref-type="fig" rid="fig1">Figure 1A–D</xref>). Following myeloid differentiation, floating myeloid progenitor cells were harvested and allowed to differentiate further for 2 weeks in 6-well plates/flask under conditions promoting microglial differentiation. We modified this step to include additional differentiation factors in the differentiation medium, including IL34, CSF1, CX3CL1, TGFB1, and TGFB2. We found that these factors promoted microglial morphological ramification and process elongation. Immunohistochemical analysis of the resulting cells showed that among CD34(+) cells, 98.6% were immunopositive for IBA1 (<xref ref-type="fig" rid="fig1">Figure 1E, F</xref>), and 98.5% were immunopositive for P2RY12 (<xref ref-type="fig" rid="fig1">Figure 1E, G</xref>). Immunostaining with myeloid cell markers CX3CR1, CD68, and CD11b showed positivity in 88%, 99.7%, and 94.3%, respectively, demonstrating the high efficiency of differentiation achieved by this procedure (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Most of the resulting hiPSC-derived microglia showed spindle-shaped morphologies, with some displaying short ramifications in their processes (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), resembling those observed in primary mouse retinal microglia cultures (<xref ref-type="bibr" rid="bib46">Ma et al., 2009</xref>). Floating myeloid progenitor cell harvest could be performed repeatedly over 3 months following culture establishment, providing a steady and consistent supply for further microglia differentiation and generation.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Differentiation and characterization of human-induced pluripotent stem cell (iPSC)-derived microglia.</title><p>(<bold>A</bold>) Human iPSCs were cultured in a 6-well plate. Scale bar = 200 µm. (<bold>B</bold>) Embryoid body formation was enabled in AggreWell800 plate at day 8 in culture medium mTeSR1 plus BMP4, VEGF, and SCF. Scale bar = 200 µm. (<bold>C</bold>) Image of a myeloid precursor cluster following 1 month culture of embryoid bodies in TheraPEAK X-vivo-15 Serum-free Hematopoietic Cell Medium with added M-CSF and IL3. Scale bar = 50 µm. (<bold>D</bold>) Image of microglial cells in maturation culture for 2 weeks with Dulbecco's Modified Eagle Medium (DMEM)/F12 plus non-essential amino acids, glutamine, IL34, CSF1, TGFb2, and CX3CL1. Scale bar = 50 µm. (<bold>E</bold>) Immunohistochemical staining for <italic>Iba1</italic> and human CD34, CX3CR1, P2RY12, CD11b, and CD68. Scale bar = 100 µm. (<bold>F</bold>) Cell counts and colocalization analysis of (<bold>F</bold>) CD34- and Iba1-positive cells and (<bold>G</bold>) positivity for myeloid cell markers CX3CR1, CD11b, activation marker CD68, and microglia marker P2RY12 in differentiated microglia.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Immunocytochemistry staining with human SPI1 and TREM2.</title><p>(<bold>A</bold>) Confocal images showed SPI1 and TREM2 staining. Scale bar = 100 μm. (<bold>B</bold>) SPI1- and TREM2-positive cells are 99.7% and 99.4%, respectively, in entire DAPI+ cell counts.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig1-figsupp1-v1.tif"/></fig></fig-group><p>A comparative RNAseq analysis between differentiated hiPSC-derived microglia collected at the end of the protocol vs. floating myeloid progenitor cells revealed a significant upregulation of microglia-enriched gene expression following microglial differentiation, including <italic>Cx3cr1</italic>, <italic>P2ry12</italic>, <italic>P2ry13</italic>, <italic>Aif1</italic>, <italic>Trem2</italic>, <italic>Gpr34</italic>, <italic>CD53</italic>, <italic>CTSS</italic>, and <italic>C3aR1</italic> (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>). Moreover, hiPSC-derived microglia exhibited higher expression of genes associated with inflammation, apoptosis regulation, phagocytosis, lipid metabolism, and immune responses. The floating myeloid progenitor cells showed higher expression of hematopoietic/myeloid cell lineage genes (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Ingenuity Pathway Analysis (IPA) of differentially expressed genes identified IL6, IL1B, and STAT3 as central signaling hubs critical to the regulation of inflammatory responses in microglia (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). We also compared the gene expression profiles between differentiated hiPSC-derived microglial cells vs. human microglia isolated ex vivo from the fetal and adult brain (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplements 2</xref>–<xref ref-type="fig" rid="fig2s4">4</xref> <xref ref-type="supplementary-material" rid="supp2 supp3">Supplementary files 2 and 3</xref>; <xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Douvaras et al., 2017</xref>; <xref ref-type="bibr" rid="bib51">Muffat et al., 2016</xref>; <xref ref-type="bibr" rid="bib8">Böttcher et al., 2019</xref>; <xref ref-type="bibr" rid="bib78">van der Poel et al., 2019</xref>; <xref ref-type="bibr" rid="bib21">Eisenberg and Levanon, 2013</xref>). The results of the correlation analysis indicated that hiPSC-derived microglial cells demonstrated an expression profile comparable to those in fetal and adult microglia in vivo but were more distinct from those in monocytes and inflammatory monocytes. Thus, our method of obtaining differentiated microglia can reliably and efficiently generate a large population of homogenous functional microglial cells of human origin.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Profiling of genes differentially expression between differentiated microglial cells vs. myeloid progenitor cells (MPCs) using bulk RNAseq analysis.</title><p>(<bold>A</bold>) Volcano plot showing representative genes that were either upregulated (red) or downregulated (green) in differentiated microglia vs. MPCs. (<bold>B</bold>) Heat map showing increased expression of microglia-enriched genes in differentiated microglia (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). (<bold>C</bold>) Histogram comparing the expression levels of microglia-enriched genes in terms of Fragments Per Kilobase of transcript per Million mapped reads (FPKM). *p &lt; 0.05. (<bold>D</bold>) Histogram comparing expression levels of myeloid cell lineage genes in human-induced pluripotent stem cell (iPSC)-derived MPC and microglia cells using FPKM. *p &lt; 0.05. (<bold>E</bold>) Graphic signaling pathway analysis with Ingenuity Pathway Analysis (IPA) highlighting <italic>IL6</italic> and <italic>IL1B</italic> as signaling hubs in differential gene expression patterns (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) in differentiated microglia vs. MPCs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Analysis results of the canonical pathway of complete differentiated human-induced pluripotent stem cell (hiPSC)-derived microglia vs. myeloid progenitor cells with Ingenuity Pathway Analysis (IPA) with the enriched microglia genes (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Hierarchical cluster analysis on microglia-enriched genes among human-induced pluripotent stem cell (hiPSC)-derived microglial cells (hiPSC-MG) and human adult brain microglia cells (AMG), fetal brain microglia cells (FMG), inflammatory monocytes (IM), monocytes (M).</title><p>The human microglia gene panel combined our mouse microglia-enriched genes and human microglia-enriched genes (<xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>; <xref ref-type="bibr" rid="bib51">Muffat et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Douvaras et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Böttcher et al., 2019</xref>; <xref ref-type="bibr" rid="bib78">van der Poel et al., 2019</xref>). The total microglia-enriched gene list contains 203 genes (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), which used to be extracted from the gene profile of human-induced pluripotent stem cell (hiPSC)-MG and downloaded human adult microglia (AMG), fetal microglia (FMG), inflammatory monocyte (IM) and monocytes (M) (GSE 178846, <xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>). 188 genes (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) were obtained from both gene lists. All the gene counts were normalized with four human cells housekeeping genes C1orf43, RAB7A, REEP5, and VCP (<xref ref-type="bibr" rid="bib21">Eisenberg and Levanon, 2013</xref>). The hierarchical cluster was analyzed by JMP (JMP Statistical Discovery LLC). Results showed that hiPSC-MG is more comparable with AMG and FMG.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Correlation analysis between the expression levels of microglia-enriched genes in human-induced pluripotent stem cell (hiPSC)-derived microglia cells (hiPSC-MG) vs. those in other myeloid cells.</title><p>The correlation analysis of 188 human microglia-enriched genes (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) among human-induced pluripotent stem cell (hiPSC)-derived microglia cells (hiPSC-MG), human adult brain microglia (AMG) cells (<bold>A</bold>), fetal brain microglia (FMG) cells (<bold>B</bold>), inflammatory monocytes (IM) (<bold>C</bold>), and monocytes (M) (<bold>D</bold>) (GSE 178846, <xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>), respectively. The images and the analysis results (Prism, GraphPad) showed that expression levels of microglia-enriched genes in hiPSC-MG are more correlated between those in FMG (<italic>r</italic> = 0.7358, p &lt; 0.0001) and AMG (<italic>r</italic> = 0.7057, p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Correlation analysis between the expression levels of genes in human-induced pluripotent stem cell (hiPSC)-derived microglia cells (hiPSC-MG) vs. human donor brain microglia by sex.</title><p>Correlation comparison of entire gene profiles between male (<bold>A</bold>)/female (<bold>B</bold>) human-induced pluripotent stem cell (hiPSC)-derived microglial cells and male (<bold>A</bold>)/female (<bold>B</bold>) human brain microglia cells (GSE 111972, <xref ref-type="bibr" rid="bib78">van der Poel et al., 2019</xref>; <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>), respectively. The results showed they are significantly correlative (<italic>r</italic> = 0.8055 (M), <italic>r</italic> = 0.8326 (F), p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig2-figsupp4-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Human iPSC-derived microglia show inflammation responses and phagocytosis activity</title><p>Microglia play crucial roles in mediating inflammatory responses to stimuli and in phagocytosing pathogens. To investigate these functions further, we stimulated hiPSC-derived microglia with lipopolysaccharide (LPS) and analyzed their responses. Transcriptomic profiling using bulk RNAseq revealed that the primary responses to LPS stimulation involved changes in <italic>IL6</italic>, <italic>IL1B</italic>, <italic>IL1A</italic>, <italic>TNFA</italic>, and <italic>IFNG</italic> signaling (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>), indicating the ability of hiPSC-derived microglia to demonstrate classical activation. This was confirmed through expression analysis using quantitative reverse transcription-PCR (qRT-PCR) and protein multiplex profiling, which showed a 50- to 800-fold increase in the expression of <italic>IL6</italic>, <italic>IL1A</italic>, <italic>IL1B</italic>, <italic>TNFA</italic>, <italic>IL8</italic>, <italic>CXCL10</italic>, and <italic>CCL2</italic> mRNA after 6 hr of LPS stimulation (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Similarly, we observed a significant increase in protein expression levels of these cytokines in cell lysate and culture medium (<xref ref-type="fig" rid="fig3">Figure 3C, D</xref>). We also treated hiPSC-derived microglia with IFNγ and a combination of IFNγ + LPS (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), and the results demonstrated that the combination of IFNγ + LPS promoted <italic>IL1A</italic>, <italic>IL1B</italic>, <italic>TNFA</italic>, <italic>CCL8</italic>, and <italic>CXCL10</italic> expression. These findings indicate that hiPSC-derived microglia, akin to microglia in vivo, exhibited strong responses to LPS and IFNγ stimulation.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Inflammation responses of human-induced pluripotent stem cell (hiPSC)-derived microglial cells following lipopolysaccharide (LPS) stimulation.</title><p>(<bold>A</bold>) Ingenuity Pathway Analysis (IPA) showed different gene expression (fold change &gt;twofold, p &lt; 0.05) between LPS-treated and control hiPSC-derived microglial cells, demonstrating activation of core pathways involving <italic>IL6</italic>, <italic>IL1A</italic>, <italic>IL1B</italic>, and <italic>IFNG</italic>. (<bold>B</bold>) Assessment of mRNA expression of selected genes for inflammatory cytokines using quantitative reverse transcription-PCR (qRT-PCR; Oligonucleotide primers are provided in Supplementary 4) demonstrated increased expression following LPS (0.1 µg/ml) stimulation for 6 hr (3-6 replicates). These changes corresponded to increases in the protein expression levels of inflammatory cytokines following 24 hr of LPS stimulation as measured with a Multiplex kit (Millipore) in cell lysate (<bold>C</bold>) and conditioned media (<bold>D</bold>). The data in (<bold>C</bold>) and (<bold>D</bold>) are presented as means ± SEM (3-6 replicates). *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Inflammatory cytokines were produced synthetically by IFNG and LPS in human-induced pluripotent stem cell (hiPSC)-derived microglial cells.</title><p>hiPSC-derived microglial cells were cultured in 6-well plates for 14 days, 20 ng/ml of human IFNG and 0.5 µg/ml of LPS were added to the wells, respectively, or 20 ng/ml of human IFNG and 0.5 µg/ml of LPS were added to the wells together. After 6 hr of incubation, the cells were washed and harvested into a 1.5-ml Eppendorf tube for RNA isolation with a NucleoSpin RNA/Protein Mini kit (Macherey-Nagel, #740933.50). The cDNA was synthesized with PrimeScript 1st strand cDNA Synthesis Kit (Takara, #6110A). Quantitative reverse transcription-PCR (qRT-PCR) was performed using a SYBR green RT-PCR kit (Affymetrix), using the Bio-Rad CFX96 Touch Real-Time PCR Detection System under the following conditions: denaturation at 95°C for 5 min, followed by 40 cycles of 95°C for 10 s, and then 60°C for 45 s. Threshold cycle (CT) values were calculated and expressed as fold-induction determined using the comparative CT (2ΔΔCT) method. Ribosomal protein S13 (RPS13) and GAPDH were used as internal controls. Oligonucleotide primers are provided in Supplementary 4, the samples have 3 replicates. .</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Microglia are local immune cells in the CNS, functioning as phagocytes involved in clearing apoptotic or necrotic cells, and cell debris (<xref ref-type="bibr" rid="bib27">Green et al., 2016</xref>), remodeling neuronal connectivity by engulfing synapses, axonal and myelin debris (<xref ref-type="bibr" rid="bib56">Paolicelli et al., 2011</xref>), and removing pathogens by direct phagocytosis (<xref ref-type="bibr" rid="bib52">Nau et al., 2014</xref>). To assess the phagocytic capability of hiPSC-derived microglia, we exposed them to three different types of bioparticles: <italic>Escherichia coli</italic> bacteria, zymosan, and bovine photoreceptor outer segments (POSs) (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>). The cells altered their morphology in response and rapidly internalized the fluorescent-labeled particles (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>). The engulfed bioparticles were condensed into perinuclear aggregates, likely within lysosomal bodies. They also demonstrated concurrent morphological changes into amoeboid-shaped cells (<xref ref-type="fig" rid="fig4">Figure 4D, E</xref>), resembling phenotypes demonstrated by retinal microglia phagocytosing photoreceptors in the context of photoreceptor degenerative pathologies in vivo (<xref ref-type="bibr" rid="bib89">Zhao et al., 2015</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Human-induced pluripotent stem cell (iPSC)-derived microglia demonstrate robust phagocytosis.</title><p>Human iPSC-derived microglia were incubated for 1 hr in pHrodo Red <italic>E. coli</italic> bioparticles (<bold>A</bold>), pHrodo Red zymosan bioparticles (<bold>B</bold>), DiI-labeled bovine photoreceptor outer segments (POSs) (<bold>C</bold>) and labeled with anti-human <italic>P2RY12</italic> antibody (green) and DAPI. Scale bar = 40 µm. (<bold>D</bold>) A high-magnification view of a POS-containing intracellular vesicle within a labeled microglial cell is shown. Scale bar = 40 µm. (<bold>E</bold>) An overlay of panels in (<bold>D</bold>) with side views. Scale bar = 40µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Floating myeloid progenitor cells were cultured in a 2-well slide chamber overnight, and then the DiI-labeled bovine photoreceptor outer segments were added to the chamber and incubated for 1 hr.</title><p>The cells were fixed with 4% paraformaldehyde (PFA) for 20 min and stained with IBA1 and hP2RY12, respectively. The DiI-labeled bovine photoreceptor outer segments can only be engulfed by IBA1- or P2RY12-positive microglia cells. Scale bar = 16 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>The morphology of human-induced pluripotent stem cell (hiPSC)-derived microglia cells under 1 hr zymosan treatment with different concentrations.</title><p>After 1 hr of treatment with zymosan, 5 µg/ml concentration did not change the microglia cell morphology, but over 20 µg/ml concentration changed the microglia morphology to an ameboid round shape.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig4-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Transition of hiPSC-derived microglial cells to a homeostatic state within the mouse retina following xenotransplantation in vivo</title><p>To assess the ability of hiPSC-derived microglia to serve as microglia donor cell sources for transplantation, we conducted xenotransplantation experiments using humanized immunodeficient Rag2<sup>−/−</sup>;IL2rg<sup>−/−</sup>;hCSF1<sup>+/+</sup> transgenic mice as recipients as previously employed (<xref ref-type="bibr" rid="bib73">Svoboda et al., 2019</xref>; <xref ref-type="bibr" rid="bib86">Xu et al., 2020b</xref>; <xref ref-type="bibr" rid="bib12">Chadarevian et al., 2023</xref>). Prior to xenotransplantation, recipient transgenic mice were pharmacologically depleted of endogenous retinal microglia by systemic administration of the CSF1R inhibitor PLX-5622 to create a depleted tissue niche for the integration of xenotransplanted microglia (<xref ref-type="bibr" rid="bib87">Zhang et al., 2018</xref>). Two days following PLX-5622 treatment, adult transgenic mice were transplanted with 5000 hiPSC-derived microglia via injection into the subretinal space (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Tissue analysis at 4 and 8 months post-transplantation revealed that transplanted cells, which were marked by either tdTomato or EGFP expression, had migrated anteriorly from the subretinal space into the neural retina and were distributed across a wide retinal area within the inner and outer retinal layers including the ganglion cell layer (GCL), IPL, and OPL (<xref ref-type="fig" rid="fig5">Figure 5B–D</xref>) in retinal loci typically occupied by endogenous microglia. Transplanted cells were immunopositive for IBA1, and human CD11b (hCD11b) (<xref ref-type="fig" rid="fig5">Figure 5H, I</xref>), as well as for microglia signature markers hP2RY12 and hTMEM119 (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Interestingly, the transplanted cells within the retina showed a ramified morphology typical of homeostatic microglia and demonstrated a regularly tiled ‘mosaic’ distribution in their soma positions. These integrated cells were juxtaposed alongside residual endogenous murine microglia, which showed similar morphology and distribution as in endogenous conditions. This indicated that transplanted hiPSC-derived microglia responded to similar intraretinal cues and inter-microglia neighbor–neighbor interactions that guide the spatial and morphological organization of retinal microglia in vivo (<xref ref-type="fig" rid="fig5">Figure 5B–G</xref>). Similar observations were made for separate experiments involving the transplantation of tdtomato- and EGFP-expressing hiPSC-derived microglia (<xref ref-type="fig" rid="fig5">Figure 5B, C, H, I</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Xenotransplanted human-induced pluripotent stem cell (iPSC)-derived microglial cells into recipient mouse retina in vivo demonstrate recapitulation of endogenous distribution, cellular morphology, and stable integration for up to 4 months.</title><p>(<bold>A</bold>) The schematic diagram shows the timeline for transplantation experiments. Two-month-old adult transgenic Rag2<sup>−/−</sup>;IL2rg<sup>−/−</sup>;hCSF1<sup>+/+</sup> mice were fed a PLX-5622-containing diet for 10 days before switching to standard chow. Two days following the resumption of standard chow, human iPSC-derived microglial cells expressing either tdTomato or EGFP were xenotransplanted into the subretinal space via subretinal injection (5000 cells in 1 µl injection volume). Retinas were harvested for analysis 120 and 240 days following transplantation. (<bold>B, C</bold>) The retinas isolated from post-transplantation were analyzed in flat-mounted tissue with confocal imaging. Transplanted human-induced pluripotent stem cell (hiPSC)-derived microglia were visualized through their expression of tdtomato (TdT) (<bold>B</bold>) or EGFP (<bold>C</bold>), while endogenous mouse microglia were visualized using immunostaining for mouse Tmem119 (mTmem119). Imaging analysis was performed in separate layers of the retina, including the ganglion cell layer (GL), inner plexiform layer (IPL), and outer plexiform layer (OPL). Scale bar = 100 µm. (<bold>D</bold>) The retinal section showed human iPSC-derived microglial cells integrated into whole retinal layers (top panel) and positively stained with human P2RY12 and TMEM119 microglia signature markers. Scale bar = 100 µm. The microglia cell number in GL, IPL, and OPL of host mouse retina were counted: mouse microglial cells (Iba1+, tdT−) and grafted human microglial cells (Iba1+, tdT+) were shown in (<bold>E</bold>), (<bold>F</bold>), and (<bold>G</bold>), respectively. ***p &lt; 0.001, ****p &lt; 0.0001, 3-6 biological replicates were performed. (<bold>H</bold>) and (<bold>I</bold>) showed tdT (<bold>H</bold>) or EGFP (<bold>I</bold>) labeled human iPSC-derived microglial cells in the IPL and OPL of the flat-mount retina with human CD11b staining. These results demonstrated that the infiltration of grafted hiPSC-derived microglial cells integrated into the mouse retina is general in nature and not cell line specific. Scale bar = 100 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Homeostatic human-induced pluripotent stem cell (hiPSC)-derived microglial cells in the mouse retina do not affect local retinal cells.</title><p>Entire section images showed GFAP, GS, RBPMS, and Iba1 staining for astrocytes, Müller cells, ganglion cells, and microglia cells in the retina after 4 months of xenotransplantation. Scale bar = 300 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Homeostatic human-induced pluripotent stem cell (iPSC)-derived microglia cells in the mouse retina do not affect local retinal cells.</title><p>The high-magnification images showed GFAP, GS, RBPMS, and Iba1 staining for astrocytes, Müller cells, ganglion cells, and microglia cells in the retina after 4 months of transplantation. Scale bar = 100 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Homeostatic human-induced pluripotent stem cell (iPSC)-derived microglia cells in the mouse retina do not affect local retinal cells.</title><p>Entire section images showed arrestin, calbindin, and PKCα staining for cone photoreceptors, horizontal and some amacrine cells, and bipolar cells in the retina after 4 months of xenotransplantation. Scale bar = 300 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig5-figsupp3-v1.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>Homeostatic human-induced pluripotent stem cell (iPSC)-derived microglia cells in the mouse retina do not affect local retinal cells.</title><p>The partial section of high-magnification images showed arrestin, calbindin, and PKCα staining for cone photoreceptors, horizontal and some amacrine cells, and bipolar cells in the retina after 4 months of xenotransplantation. Scale bar = 100 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig5-figsupp4-v1.tif"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 5.</label><caption><title>Homeostatic human-induced pluripotent stem cell (iPSC)-derived microglia cells in the mouse retina do not take over local retinal microglia cells.</title><p>The section images showed Red Fluorescence Protein (RFP) and mouse CD11b staining to determine the tdT+ human microglia cells and local mouse microglia cells in the retina after 4 months of xenotransplantation. The results showed that the tdT+ human microglia cells colocalized with RFP staining (Far red) but not mouse CD11b (green) staining. Scale bar = 100 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig5-figsupp5-v1.tif"/></fig><fig id="fig5s6" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 6.</label><caption><title>Homeostatic human-induced pluripotent stem cell (iPSC)-derived microglia cells in the mouse retina do not take over local retinal microglia cells.</title><p>The hight magnification images showed RFP and mouse CD11b staining in the retina after 4 months of xenotransplantation. The results showed that the tdT+ human cells colocalized with RFP staining (Far red) but not mouse CD11b (green) staining. The triangle marker indicated that the local mouse microglia cells were only stained with mouse CD11b but not colocalized with tdT+ human microglia cells. Scale bar = 50 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig5-figsupp6-v1.tif"/></fig></fig-group><p>We further evaluated the impact of human iPSC-derived microglia xenotransplantation on the host mouse retinal cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s6">6</xref>). We examined the effect of microglia transplantation on endogenous Müller cell morphology and gliosis markers as retinal microglia have been described to interact with Müller glia to regulate overall retinal neuroinflammatory response (<xref ref-type="bibr" rid="bib80">Wang et al., 2014</xref>). Immunostaining with glial fibrillary acidic protein (GFAP) and glutamine synthetase (GS) antibody (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref> and <xref ref-type="fig" rid="fig5s2">2</xref>) indicated that the transplanted human iPSC-derived microglial cells did not trigger any upregulation of Müller cell gliosis markers or induced morphological changes or reactive proliferation for up to 4 months post-transplantation. Additionally, the laminar organization of the inner and outer retinal layers remained normal and similar to those in control retinas not subjected to transplantation (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s4">4</xref>), indicating that microglia transplantation had no adverse impact on the structural integrity of the retina. Furthermore, immunostaining with the mouse CD11b antibody, which marked the residual population of endogenous mouse microglia showed the spatial juxtaposition of these mouse microglia with transplanted human iPSC-derived microglia in a common mosaic of tiled cells (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplements 5</xref> and <xref ref-type="fig" rid="fig5s6">6</xref>), indicating the ability of transplanted hiPSC-derived microglia to integrate with and exchange signals with the residual endogenous microglial population, but not replaced.</p></sec><sec id="s2-4"><title>Transplanted hiPSC-derived microglia respond to induction of RPE cell injury with migration and proliferation</title><p>To monitor the longer-term consequences of microglia xenotransplantation, we extended analysis and examined the location and morphology of transplanted hiPSC-microglia up to 8 months post-transplantation. Analysis of retinal flat mounts confirmed that the tdTomato+ cells remained appropriately located in the GCL, IPL, and OPL, forming a mosaic-like distribution typical of endogenous microglia (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplements 1</xref> and <xref ref-type="fig" rid="fig6s2">2</xref>). These cells maintained expression of hP2RY12 and hTMEM119, markers of homeostatic retinal microglia, indicating their long-term integration within the recipient mouse retina.</p><p>To evaluate the function of the transplanted hiPSC-derived microglia in the mouse retina and their ability to respond to injury in vivo, we subjected recipient mice 240 days post-transplantation to sodium iodate (NaIO<sub>3</sub>)-mediated RPE injury and analyzed retinal tissue 3 and 7 days post-injury (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). In a previous study (<xref ref-type="bibr" rid="bib49">Ma et al., 2017</xref>), we had characterized the responses of endogenous retinal microglia in this injury model; in the few days following injury, microglia within the neural retina migrated into the subretinal space, coming into close proximity to damaged RPE cells. This resulted in a transient decrease in microglia number in the IPL and OPL, which then recovered partially following the proliferation of the remaining microglia to replenish the depleted areas. We found that transplanted hiPSC-derived microglia demonstrated responses similar to endogenous microglia. Three days after NaIO<sub>3</sub> injury, there was an increase in tdTomato+, hP2ry12+, hiPSC-derived microglia in the subretinal space, while their number decreased in the IPL and OPL (<xref ref-type="fig" rid="fig6">Figure 6B–D, G</xref>), indicating a migration of these cells from the neuroretina to the subretinal space. Some of the remaining tdTomato+ and P2ry12+ cells in the inner retina were positive for the cell-proliferation marker Ki67, indicating active cell division (<xref ref-type="fig" rid="fig6">Figure 6B–D, F</xref>). The numbers of Ki67+ tdTomato+ microglia peaked at 3 days post-injury and decreased thereafter (<xref ref-type="fig" rid="fig6">Figure 6B–F</xref>). Seven days post-injury, the numbers of tdTomato+ and P2ry12+ human iPSC-derived microglia increased in the IPL and OPL but decreased in the subretinal space (<xref ref-type="fig" rid="fig6">Figure 6E, G</xref>); Ki67+ tdTomato+ cell numbers also declined (<xref ref-type="fig" rid="fig6">Figure 6E, F</xref>). These findings suggest that once the hiPSC-derived microglia had replenished endogenous numbers in the inner retina, their division ceased. This response mirrors that of the endogenous mouse retinal microglia to NaIO<sub>3</sub> injury (<xref ref-type="bibr" rid="bib49">Ma et al., 2017</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Migration and proliferation of human-induced pluripotent stem cell (hiPSC)-derived microglia in the mouse retina after sodium iodate (NaIO<sub>3</sub>)-induced retinal pigment epithelial (RPE) cell injury.</title><p>(<bold>A</bold>) The schematic diagram shows the experiment’s procedure. After 8 months post-transplantation of hiPSC-derived microglia, recipient animals were administered NaIO<sub>3</sub> (30 mg/kg body weight, intraperitoneal injection) to induce RPE injury. Retinas were harvested at 3 and 7 days after NaIO<sub>3</sub> administration and microglia numbers in the retina and subretinal space will be monitored in retina and RPE-choroid flat mounts. (<bold>B</bold>) RPE-choroid flat mounts demonstrate an increase of hiPSC-derived microglia (tdTomato+ and P2RY12+) in the subretinal space in response to RPE injury. A subset of subretinal microglia labeled for Ki67 indicates active proliferation. Scale bar = 60 µm. (<bold>C</bold>) and (<bold>D</bold>) showed the number of P2RY12+ and tdtomato+ human microglial cells in inner plexiform layer (IPL) (<bold>C</bold>) and outer plexiform layer (OPL) (<bold>D</bold>) decreased; some of them showed Ki67+ staining, Scale bar = 60 µm. The cell count results showed in (<bold>F</bold>) and (<bold>G</bold>). (<bold>E</bold>) The retinal flat mount showed the number of P2RY12+ and tdtomato+ human microglial cells in IPL and OPL that were repopulated, and the cells stopped dividing with loss of the Ki67 staining at 7 days after NaIO<sub>3</sub> injection. The cell numbers are shown in (<bold>F</bold>) and (<bold>G</bold>) (3 biological replicates). Scale bar = 60 µm, ** P&lt;0.01, *** P&lt;0.001, **** P,0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>The images of hP2RY12 staining on the retina after 8 months of xenotransplantation.</title><p>The images showed the tdtomato+ human microglia cells colocalized with hP2RY12 staining in GL, inner plexiform layer (IPL), and outer plexiform layer (OPL) in the mouse retina. Scale bar = 300 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>The images of hTMEM119 staining on the retina after 8 months of xenotransplantation.</title><p>The images showed the tdtomato+ human microglia cells colocalized with hTMEM119 staining in GL, inner plexiform layer (IPL), and outer plexiform layer (OPL) in the mouse retina. Scale bar = 300 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig6-figsupp2-v1.tif"/></fig></fig-group><p>Overall, these results demonstrate that the transplanted human iPSC-derived microglial cells retained a capacity for migration and proliferative responses to injury in a manner observed for endogenous microglia.</p></sec><sec id="s2-5"><title>hiPSC-derived microglial cells phagocytize debris or dead photoreceptor cells after NaIO<sub>3</sub>-induced RPE cell injury</title><p>Phagocytosis, a critical function of microglia, is essential both during development and in the resolution of pathological processes. Retinal microglia adaptively phagocytose and clear apoptotic photoreceptors in the rd10 mouse model of photoreceptor degeneration (<xref ref-type="bibr" rid="bib70">Silverman et al., 2019</xref>). We found here that 3 days following NaIO<sub>3</sub>-induced RPE cell injury, tdTomato+ transplanted hiPSC-derived microglia migrated not only to the subretinal space but also into the photoreceptor layer (<xref ref-type="fig" rid="fig7">Figure 7A–C</xref>), coincident with the time of photoreceptor degeneration, when photoreceptor morphology becomes disrupted and photoreceptor density decreases (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Within the photoreceptor layer, hiPSC-derived microglia were observed to phagocytose photoreceptors as evidenced by the accumulation of intracellular autofluorescent material in their soma (<xref ref-type="fig" rid="fig7">Figure 7A, B, D</xref>), and their transformation into larger amoeboid cells (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, yellow arrowhead) containing arrestin-immunopositive photoreceptor-derived debris. mRNA analysis for human-specific transcripts also indicated that transplanted hiPSC-derived microglia upregulated inflammatory cytokine expression, increased phagocytosis, and decreased expression of microglia homeostatic genes and neurotrophic factors (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>; <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Taken together, these findings further demonstrate that the xenografted human iPSC-derived microglial cells generate functional responses to in vivo injury that closely resemble those of endogenous homeostatic retinal microglia.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Dyshomeostatic human-induced pluripotent stem cell (iPSC)-derived microglial cells in the mouse retina phagocytose dead photoreceptor cells/debris after retinal pigment epithelial (RPE) cell injury.</title><p>(<bold>A</bold>) Dyshomeostatic human microglial cells (tdtomato+) accumulated in the photoreceptor cell layer after 3 days of sodium iodate (NaIO<sub>3</sub>)-induced RPE cell injury compared with no NaIO<sub>3</sub> administration. The photoreceptor cells stained with cone arrestin (green) and autofluorescence showed in magenta. Scale bar = 60 µm. (<bold>B</bold>) High-magnificent images and the side view showed human microglial cells (red) co-labeled with photoreceptor cells arrestin staining (green) after 3 days of NaIO<sub>3</sub> injury. The yellow arrowhead showed the colocalized tdT+ human microglia cell and arrestin+ cone photoreceptor cell. Scale bar = 40 µm. (<bold>C</bold>) The number of tdtomato+ human microglial cells in the photoreceptor layer. (<bold>D</bold>) The mean gray autofluorescence value in each human microglia cell. ****p &lt; 0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>The inflammation, phagocytosis, adhesion and migration, neurotrophic factors, and microglia signature gene expression in human-induced pluripotent stem cell (hiPSC)-derived microglia cells of grafted retinas.</title><p>The gene coding sequences were compared between humans and mice, a human-specific sequence was chose to make the oligos (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>), and ran a quantitative reverse transcription-PCR (qRT-PCR) on 8-month hiPSC-derived microglia cells grafted retinas with/without sodium iodate (NaIO<sub>3</sub>)-treated retinas. The results revealed that hiPSC-derived microglia cells expressed more inflammatory factors and phagocytosis genes and promoted cell migration but decreased microglia cell signature genes and neurotrophic factors in NaIO<sub>3</sub>-treated retina (3 biological replicates in each group).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig7-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Microglial cells are instrumental in the development and progression of numerous CNS diseases. For instance, in AD, microglia are enriched in over 50% of associated gene loci implicated in AD risk (<xref ref-type="bibr" rid="bib32">Hasselmann and Blurton-Jones, 2020</xref>). Similarly, in AMD, 57% of 368 genes, located close to 52 AMD gene loci, are expressed in retinal microglial cells (Figure 9), and 52% of them are highly expressed in microglial cells (<xref ref-type="fig" rid="fig8">Figures 8</xref> and <xref ref-type="fig" rid="fig9">9</xref>; <xref ref-type="bibr" rid="bib24">Fritsche et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Ma et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">den Hollander et al., 2022</xref>). Understanding microglia cell functions is essential for investigating disease mechanisms and identifying accurate therapeutic targets. Most of our current knowledge about microglial cells comes from rodent studies. However, genetic and functional differences exist between murine and human microglia (<xref ref-type="bibr" rid="bib25">Galatro et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Gosselin et al., 2017</xref>; <xref ref-type="bibr" rid="bib71">Smith and Dragunow, 2014</xref>). Hence, more in-depth knowledge of human microglial cells in vitro and in vivo is required.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>The heat map of 42 candidate genes from 34 loci associated with age-related macular degeneration (AMD) expressed in retinal microglia cells.</title><p>The microglia gene expression data are from microarray data previously published (<xref ref-type="bibr" rid="bib48">Ma et al., 2013</xref>). The candidate genes came from the published paper (<xref ref-type="bibr" rid="bib19">den Hollander et al., 2022</xref>). The gene list is in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig8-v1.tif"/></fig><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>The heat map of 209 genes associated with age-related macular degeneration (AMD) (<xref ref-type="bibr" rid="bib24">Fritsche et al., 2016</xref>) expressed in retinal microglia cells.</title><p>The microglia gene expression data are from microarray data previously published (<xref ref-type="bibr" rid="bib48">Ma et al., 2013</xref>). The gene list is in <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-fig9-v1.tif"/></fig><p>Human iPSCs offer promising prospects for many retinal research fields (<xref ref-type="bibr" rid="bib90">Zhong et al., 2014</xref>; <xref ref-type="bibr" rid="bib41">Leach et al., 2016</xref>; <xref ref-type="bibr" rid="bib75">Tanaka et al., 2016</xref>). For over a decade, macrophage/microglial cells have been differentiated using human iPSC (<xref ref-type="bibr" rid="bib37">Karlsson et al., 2008</xref>; <xref ref-type="bibr" rid="bib60">Pocock and Piers, 2018</xref>). An abundance of hiPSC-derived microglial cells, with defined genomic background and easy manipulation of hiPSC, offer substantial benefits in various research areas.</p><p>Under in vivo physiological conditions, microglial cells exhibit a tile-like arrangement, without overlap. They try to maintain this property in culture, allowing overgrown cells to float out to the medium. Based on this phenomenon and a variety of established microglia cell differentiation protocols (<xref ref-type="bibr" rid="bib51">Muffat et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Pandya et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Douvaras et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Haenseler et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Takata et al., 2017</xref>), We chose to employ the myeloid progenitor/microglia cell floating culture method (described in <xref ref-type="bibr" rid="bib79">van Wilgenburg et al., 2013</xref>; <xref ref-type="bibr" rid="bib30">Haenseler et al., 2017</xref>) due to its simplicity, efficiency, and consistency. This approach facilitates the generation of a large and uniform population of myeloid progenitor cells, with over 98.6% expressing the <italic>CD34</italic> marker, sustained over a 3-month period. These progenitor cells differentiate into pure microglial cells (&gt;98.5% <italic>P2RY12+</italic>), bearing a profile rich in microglia genes, and demonstrate characteristics similar to native microglia in physiological CNS tissue. A comparison of the signaling pathway to myeloid cells reveals the central hubs of signaling as IL6, IL1b, and the stat3 pathway (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), which are key to microglia functioning during inflammation. The differentiation protocol employing floating myeloid progenitor cells produces a significant number of CNS resident-like microglial cells. These hiPSC-derived microglial cells respond robustly to LPS stimulation and demonstrate phagocytic activity, mimicking primary cultured retinal microglial cells. Gene expression profile comparison between hiPSC-microglial cells and fetal/adult brain microglia revealed that hiPSC-derived microglial cells are comparable to fetal and adult microglial cells but are far away from monocytes and inflammatory monocytes (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplements 2</xref>–<xref ref-type="fig" rid="fig2s4">4</xref>; <xref ref-type="supplementary-material" rid="supp2 supp3">Supplementary files 2 and 3</xref>). Therefore, they effectively replicate resident microglia characteristics (<xref ref-type="bibr" rid="bib77">Ulland and Colonna, 2018</xref>; <xref ref-type="bibr" rid="bib82">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib67">Shi et al., 2022</xref>; <xref ref-type="bibr" rid="bib29">Guo et al., 2022</xref>).</p><p>CNS disease treatment strategies include gene regulation, gene delivery (<xref ref-type="bibr" rid="bib53">Neumann, 2006</xref>; <xref ref-type="bibr" rid="bib5">Beutner et al., 2013</xref>), rejuvenation (<xref ref-type="bibr" rid="bib38">Karlstetter et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Elmore et al., 2018</xref>), or replacement of dysfunctional microglial cells (<xref ref-type="bibr" rid="bib83">Willis et al., 2020</xref>; <xref ref-type="bibr" rid="bib85">Xu et al., 2020a</xref>; <xref ref-type="bibr" rid="bib31">Han et al., 2020</xref>; <xref ref-type="bibr" rid="bib68">Shibuya et al., 2022</xref>). hiPSC-derived microglial cells offer a potentially unlimited source for cell replacement therapy. The in vivo functionality of these cells was verified through xenografting into adult Rag2−/−; IL2rg−/−;hCSF1+/+ mice. The grafted microglial cells integrated into the right location of the retina, expressing microglia signature genes and formed new homeostasis with resident microglial cells for 8 months. Homeostatic hiPSC-derived microglia responded to RPE cell injury like host retinal microglial cells, marking the success of the xenotransplantation model (<xref ref-type="bibr" rid="bib28">Guilliams and Scott, 2017</xref>) and highlighting the potential for hiPSC-derived microglial cells in retinal microglia cell replacement therapy, such as in AMD.</p><p>Several exogenous microglia cell replacement techniques have been investigated, with these methods varying based on the type of donor cells used and the recipient’s age. Initial microglia cell replacement studies started from the transplantation of hematopoietic stem cells (HPSCs) (<xref ref-type="bibr" rid="bib40">Larochelle et al., 2016</xref>; <xref ref-type="bibr" rid="bib86">Xu et al., 2020b</xref>; <xref ref-type="bibr" rid="bib33">Hohsfield et al., 2020</xref>). However, even after differentiation in local tissue, HPSC-derived microglial cells maintained some gene expressions distinct from the original resident microglial cells (<xref ref-type="bibr" rid="bib44">Lund et al., 2018</xref>), warranting further exploration of these HPSC-derived microglial cells’ unique characteristics. Another method involves using newborn mice as recipients, with iPSC or stem cell-derived microglial cells as the donors (<xref ref-type="bibr" rid="bib50">Mancuso et al., 2019</xref>; <xref ref-type="bibr" rid="bib85">Xu et al., 2020a</xref>). This approach does not require the depletion of resident microglial cells, and the grafted cells can infiltrate the brain tissue, distributing similarly to the original resident microglial cells. While suitable for examining microglia cell function in various backgrounds, the clinical applicability of this method remains limited.</p><p>A third transplantation approach involves adult recipients receiving iPSC or stem cell-derived microglial cells after resident microglia cell depletion (<xref ref-type="bibr" rid="bib12">Chadarevian et al., 2023</xref>). Since this technique requires a microglial-empty niche, resident microglia must be depleted or relocated from the retina, typically done by using CSF1R inhibitors. To prevent these inhibitors from affecting the grafted cells, investigators have tried using modified CSF1R microglial cells as donor cells (<xref ref-type="bibr" rid="bib12">Chadarevian et al., 2023</xref>). In our research, we found a 2-day recovery period with normal food intake sufficient to clear the CSF1R inhibitor, allowing grafted cells to integrate into microglia empty niche. In this study, we used the subretinal xenotransplantation method, though alternative transplantation routes such as intravenous injection, vitreous, and suborbital space delivery warrant further exploration.</p><p>In conclusion, hiPSCs can be differentiated into microglial cells through a simplified common pathway and factors, although the more precise differentiation factors still need further investigation under in vitro conditions. For instance, the microglia signature gene, TMEM119, shows low expression in hiPSC-derived microglia single-type cell culture conditions. Interestingly, we discovered that a medium composed of a mix of cultured EBs and microglia progenitor cells fosters further differentiation of microglial cells. The humanized mouse model established through xenotransplantation serves as a reliable tool for studying the functions of various hiPSC-derived microglial cells. This model offers a valuable platform for investigating disease mechanisms and evaluating the therapeutic effects of xenografted hiPSC-derived microglial cells from variety of backgrounds.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>C;129S4-Rag2tm1.1Flv Csf1tm1(CSF1)Flv Il2rgtm1.1Flv/J</italic></td><td align="left" valign="bottom">PubMed:21791433</td><td align="left" valign="bottom">MGI:J:177073</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:017708">IMSR_JAX:017708</ext-link></td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>KYOUDXR0109B</italic></td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">ACS-1023</td><td align="left" valign="bottom">Human-induced pluripotent stem cells (iPSCs)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>NCRM6</italic></td><td align="left" valign="bottom">NHLBI</td><td align="left" valign="bottom">NCRM6 (female) iPSC line</td><td align="left" valign="bottom">From CD34<sup>+</sup> cells, Episomal vectors</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>MS19-ES-H</italic></td><td align="left" valign="bottom">NHLBI</td><td align="left" valign="bottom">MS19-ES-H (female) iPSC line</td><td align="left" valign="bottom">From PBMS cells, Cytotune Sendai Virus kit</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>NCRM5-AAVS1-CAG-EGFP</italic></td><td align="left" valign="bottom">NHLBI</td><td align="left" valign="bottom">NCRM5-AAVS1-CAG-EGFP (clone 5)</td><td align="left" valign="bottom">From CD34<sup>+</sup> cells, NCRM5 (male) reporter iPSC line with CAG-EGFP targeted mono-allelically at AAVS1 safe harbor</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>ND2-AAVS1-iCAG-tdTomato</italic></td><td align="left" valign="bottom">NHLBI</td><td align="left" valign="bottom">ND2-AAVS1-iCAG-tdTomato (clone 1)</td><td align="left" valign="bottom">From fibroblast cells, ND2 (male) reporter iPSC line with insulated CAG-tdTomato targeted mono-allelically at AAVS1 safe harbor</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Iba1 (rabbit polyclonal)</td><td align="left" valign="bottom">Wako</td><td align="left" valign="bottom">Cat. #: 019-19741, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_839504">AB_839504</ext-link></td><td align="left" valign="bottom">IHC (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-human TMEM119 (rabbit polyclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: HPA051870, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2681645">AB_2681645</ext-link></td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-human CD68 (mouse monoclonal)</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">Cat. #: MAB20401</td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-human CD45 (mouse monoclonal)</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">Cat. #: FAB1430R</td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-human CD11b (mouse monoclonal)</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">Cat. #: FAB1699R</td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-human CX3CR1 (rat monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: 61-6099-42</td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-human HLA (mouse monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: 11-9983-42</td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-mouse CD11b (rat monoclonal)</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat. #: MCA711G</td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-GFAP (rat monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: 13-0300, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2532994">AB_2532994</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-mouse TMEM119 (guinea pig polyclonal)</td><td align="left" valign="bottom">Synaptic systems</td><td align="left" valign="bottom">Cat. #: 400 004, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2832239">AB_2832239</ext-link></td><td align="left" valign="bottom">IHC (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-CD68 (rat monoclonal)</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat. #: MCA1957, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_322219">AB_322219</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-CD34 (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat. #: 14-0341</td><td align="left" valign="bottom">IHC (1:30)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-PU.1 (rabbit monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: MA5-15064</td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Trem2 (rabbit monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 702886</td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-CD45 (rat monoclonal)</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat. #: MCA1388, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_321729">AB_321729</ext-link></td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti glutamine synthetase (mouse monoclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat. #: MAB302, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2110656">AB_2110656</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-RBPMS (guinea Pig polyclonal Ab)</td><td align="left" valign="bottom">Phosphosolutions</td><td align="left" valign="bottom">Cat. #: 1832-RBPMS</td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-cone arrestin (rabbit polyclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat. #: AB15282, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1163387">AB_1163387</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-calbindin (rabbit polyclonal)</td><td align="left" valign="bottom">Swant</td><td align="left" valign="bottom">Cat. #: CB-38a</td><td align="left" valign="bottom">IHC (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-PKCa (rabbit polyclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: P4334, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_477345">AB_477345</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-RFP (rabbit polyclonal)</td><td align="left" valign="bottom">RockLand</td><td align="left" valign="bottom">Cat. #: 600-401-379-RTU</td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Ki67-660 (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat. #: 50-5698-82, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2574235">AB_2574235</ext-link></td><td align="left" valign="bottom">IHC (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-P2RY12 (rabbit polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: PA5-77671, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2736305">AB_2736305</ext-link></td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-P2RY12 (rabbit polyclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: HPA014518, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2669027">AB_2669027</ext-link></td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Rabbit IgG Alexa Fluor 488</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A27034, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2536097">AB_2536097</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Rabbit IgG Alexa Fluor 568</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A11011, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_143157">AB_143157</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Rabbit IgG Alexa Fluor 647</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A32733, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2633282">AB_2633282</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG Alexa Fluor 488</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A28175, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2536161">AB_2536161</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG Alexa Fluor 568</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A-11004, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_141371">AB_141371</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG Alexa Fluor 647</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A-21235, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_141693">AB_141693</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-Rat IgG Alexa Fluor 488</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A-21208, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_141709">AB_141709</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-Rat IgG Alexa Fluor 594</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: A-21209, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2535795">AB_2535795</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-Rat IgG Alexa Fluor 650</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: SA5-10029, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2556609">AB_2556609</ext-link></td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti CD11b, Alexa Fluor 488</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat. #: 53-0112-82, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_469901">AB_469901</ext-link></td><td align="left" valign="bottom">IHC (1:50)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">human M-CSF</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: PHC9501</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Human IL3</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">Cat. #: 203-IL-100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">human IL-34</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">Cat. #: 200–34</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">human CX3CL1</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">Cat. #: 300–31</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">human TGFb1</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">Cat. #: 7666-MB-005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">human TGFb2</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">Cat. #: 7346-B2-005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">human BMP-4</td><td align="left" valign="bottom">GIBCO</td><td align="left" valign="bottom">Cat. #: PHC9534</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">human SCF</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat. #: 130096692</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">human VEGF</td><td align="left" valign="bottom">GIBCO</td><td align="left" valign="bottom">Cat. #: PHC9394</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">PLX5622</td><td align="left" valign="bottom">Plexxikon</td><td align="left" valign="bottom">PLX5622 was provided by Plexxikon Inc and formulated in AIN-76A standard chow by Research Diets Inc</td><td align="char" char="." valign="bottom">1200 mg/kg in chow</td></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">NaIO<sub>3</sub></td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: S4007</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">BSA</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: A2153</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">FBS</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: A3160702</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Ketamine</td><td align="left" valign="bottom">Anased</td><td align="left" valign="bottom">Cat. #: NDC13985-584-10</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Xylazine</td><td align="left" valign="bottom">Anased</td><td align="left" valign="bottom">Cat. #: NDC59399-110-20</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Topical tropicamide</td><td align="left" valign="bottom">Alcon</td><td align="left" valign="bottom">Cat. # 215340</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Phenylephrine</td><td align="left" valign="bottom">Alcon</td><td align="left" valign="bottom">Cat. l# 215664</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">0.5% Proparacaine HCL</td><td align="left" valign="bottom">Sandoz</td><td align="left" valign="bottom">Cat. #: 101571</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Surcrose</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: S7903-5KG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">OCT</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 23-730-571</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Fluorescein AK-FLUOR</td><td align="left" valign="bottom">Akorn</td><td align="left" valign="bottom">Cat. #: 17478-253-10</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Tamoxifen</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: T5648-5G</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">HBSS</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: H8264-1L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom"><sc>L</sc>-(+)-Cysteine hydrochloride monohydrate</td><td align="left" valign="bottom">Fisher</td><td align="left" valign="bottom">Cat. #: C562-25</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Papain, lyophilized</td><td align="left" valign="bottom">Worthington Biochemical</td><td align="left" valign="bottom">Cat. #: LS003119</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">DNAse I</td><td align="left" valign="bottom">Worthington Biochemical</td><td align="left" valign="bottom">Cat. #: LS006333</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Superoxide dismutase</td><td align="left" valign="bottom">Worthington Biochemical</td><td align="left" valign="bottom">Cat. #: LS003540</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Catalase</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: C1345-1G</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">(+)-α-Tocopherol acetate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: T-1157-1G</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Gentamicin solution</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: G1397-10ml</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom"><sc>D</sc>-(+)-Glucose</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: G7021-100g</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Antipain dihydrochloride</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat. #: 11004646001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">HEPES</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: 15630080</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">EDTA</td><td align="left" valign="bottom">KD medical</td><td align="left" valign="bottom">Cat. #: RGC-3130</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">RNAlater solution</td><td align="left" valign="bottom">Ambion</td><td align="left" valign="bottom">Cat. #: AM7021</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Triton X-100</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: X100100ml</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Tween 20</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: P1379-100ml</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Paraformadehyde</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 50-259-97</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Donkey serum</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: D9663-10ml</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Goat serum</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: G9023-10ml</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Bloking Reagent</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: 11096176001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">In Situ Cell Death Detection Kit, TMR red</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: 12156792910</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Ib4 Alexa Fluor 568</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: I21412</td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Ib4 Alexa Fluor 647</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat. #: I32450</td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DAPI</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: D9542</td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mounting medium without DAPI</td><td align="left" valign="bottom">Vector</td><td align="left" valign="bottom">Cat. #: H-1000</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mounting medium with DAPI</td><td align="left" valign="bottom">Vector</td><td align="left" valign="bottom">Cat. #: H-1200</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Mini Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">Cat. #: 74104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Rnase free Dnase set</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">Cat. #: 79254</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">First strand cDNA synthesis</td><td align="left" valign="bottom">Takara</td><td align="left" valign="bottom">Cat. #: 6110A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">MessageBooster cDNA synthesis kit</td><td align="left" valign="bottom">Epicentre</td><td align="left" valign="bottom">Cat. #: MB060110</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Fast SYBR Green Master Mix</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 4385617</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LiDirect Lightening genotyping kit</td><td align="left" valign="bottom">LifeSci</td><td align="left" valign="bottom">Cat. #: M0015</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">eBioscience Flow Cytometry Staining Buffer</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 00-4222-57</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">X-VIVO-15 medium</td><td align="left" valign="bottom">Lonza</td><td align="left" valign="bottom">Cat. #: BEBP02-061Q</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DMEM:F12 medium</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 11330057</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">mTeSR1</td><td align="left" valign="bottom">Stemcell technologies</td><td align="left" valign="bottom">Cat. #: 85850</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">N2 supplement</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 17502048</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Non-essential Amino Acids (NEAA)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 11140050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">GlutaMax Supplement</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 35050061</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Geltrex</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: A1413301</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TrypLE Express</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 12605010</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Rho-kinase inhibitor Y-27632</td><td align="left" valign="bottom">abcam</td><td align="left" valign="bottom">Cat. #: ab143784</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">mFreSR</td><td align="left" valign="bottom">Stemcell technologies</td><td align="left" valign="bottom">Cat. # 05854</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Stem Cell Dissociation Reagent</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat, #: ACS-3010</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Stem Cell Freezing Media</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat. #: ACS-3020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Penicillin-Streptomycin</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 15140122</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">pHrodo Red <italic>E. coli</italic> BioParticles</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: P35361</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">pHrodo Red Zymosan Bioparticles</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: P35364</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Bovine rod outer segment</td><td align="left" valign="bottom">Invision Bioresources</td><td align="left" valign="bottom">Cat. #: 98740</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Vybrant DiI Cell-Labeling Solution</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: V22885</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Lipopolysaccharides (LPS)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: L2630</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RIPA lysis buffer</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat. #: R0278</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">proteinase inhibitor mixture</td><td align="left" valign="bottom">Calbiochem</td><td align="left" valign="bottom">Cat. #: 539132</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA Protein Assay Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 23227</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Milliplex bead assay kit</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat. #: MCYTOMAG-70K</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">AggreWellsTM800</td><td align="left" valign="bottom">Stemcell technologies</td><td align="left" valign="bottom">Cat. #: 34825</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">ImageJ (<ext-link ext-link-type="uri" xlink:href="http://imagej.nih.gov/ij/">http://imagej.nih.gov/ij/</ext-link>)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">GraphPad Prism7</td><td align="left" valign="bottom">GraphPad Prism (<ext-link ext-link-type="uri" xlink:href="https://graphpad.com">https://graphpad.com</ext-link>)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015807">SCR_015807</ext-link></td><td align="left" valign="bottom">Version 7</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">IPA</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008653">SCR_008653</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">JMP</td><td align="left" valign="bottom">JMP</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014242">SCR_014242</ext-link></td><td align="left" valign="bottom">Version 12</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Experimental animals and PLX-5622 treatment</title><p>In vivo experiments were conducted according to protocols (NEI-698) approved by the Institutional Animal Care and Use Committee (National Eye Institute Animal Care and Use Committee) and adhered to the Association for Research in Vision and Ophthalmology (ARVO) statement on animal use in ophthalmic and vision research. Rag2<sup>−/−</sup>;IL2rg<sup>−/−</sup>;hCSF1<sup>+/+</sup> transgenic mice were obtained from Jackson Laboratories (Stock #17708). Animals were housed in a National Institutes of Health (NIH) animal facility under a 12-hr light/dark cycle and fed standard chow. Genotype analysis by sequencing revealed that the rd8 mutation was absent in the <italic>Crb1</italic> gene. To deplete retinal microglia, 2-month-old experimental animals were administered a diet containing PLX-5622 (Plexxikon, at 1200 parts per million), a potent and selective inhibitor of the CSF1R previously demonstrated to deplete the majority of microglia in the mouse brain (<xref ref-type="bibr" rid="bib17">Dagher et al., 2015</xref>) and retina (<xref ref-type="bibr" rid="bib87">Zhang et al., 2018</xref>). Animals were maintained continuously on the PLX-5622 diet for 10 days and then switched back to standard chow.</p></sec><sec id="s4-2"><title>Human iPSC culture</title><p>Five human iPSC lines were used in this study. The KYOUDXR0109B hiPSC line was generated in Yamanaka Lab from fibroblasts isolated from a healthy female donor and reprogrammed by the expression of OCT4, SOX2, KLF4, and MYC using retroviral transduction. Cells are tested for postfreeze viability and growth, sterility (including mycoplasma), identity by short-tandem repeat (STR) analysis and karyotype by G-banding. Each lot is tested for pluripotency using flow cytometry for the expression of the pluripotent markers (KYOUDXR0109B Human Induced Pluripotent Stem (IPS) Cells [201B7] (ATCC ACS1023)). The line of NCRM5-AAVS1-CAG-EGFP (clone 5), ND2-AAVS1-iCAG-tdTomato (clone 1), NCRM6, and MS19-ES-H were obtained from the NHLBI iPSC Core Facility of National Heart, Lung and Blood Institute (NHLBI). NCRM5-AAVS1-CAG-EGFP is an EGFP-expressing reporter iPSC line with CAG-EGFP targeted mono-allelically at the AAVS1 safe harbor locus in NCRM5 iPSCs. These iPSCs were reprogrammed from CD34<sup>+</sup> peripheral blood mononuclear cells (PBMCs) from a healthy male donor and the cell line was authenticated (<xref ref-type="bibr" rid="bib45">Luo et al., 2014</xref>). ND2-AAVS1-iCAG-tdTomato is a tdTomato-expressing reporter iPSC line with insulated CAG-tdTomato targeted mono-allelically at the AAVS1 safe harbor locus in ND2 iPSCs. These ND2-AAVS1-iCAG-tdTomato (clone1) cell line was reprogrammed using healthy male fibroblast cells and was authenticated by STR profiling performed by WiCell Cytogenetics lab using a Powerplex 16 System (Promega) and genomic DNA extracted from the iPSCs with DNeasy Blood and Tissue Kit (QIAGEN) (<xref ref-type="bibr" rid="bib59">Patterson et al., 2020</xref>). Microglia differentiated from these two reporter lines were used for the xenotransplantation experiments. The MS19-ES-H line was reprogrammed from PBMCs from a healthy female donor with a Cytotune Sendai Virus kit (Thermo Fisher). The STR profiling was performed by WiCell Cytogenetics lab using a Powerplex 16 System (Promega) and genomic DNA extracted from the iPSCs with DNeasy Blood and Tissue Kit (QIAGEN) (<xref ref-type="bibr" rid="bib58">Patterson et al., 2019</xref>). NCRM6 iPSC line was reprogrammed from CD34<sup>+</sup> PBMCs from a healthy female donor with episomal iPSC reprogramming vectors (Thermo Fisher). This cell line was authenticated by Cell Line Genetics for STR service using the above same method. All hiPSC lines used in this study were determined by mycoplasma with MycoAlert (Lonza’s MycoAlert Plus kit) and excluded mycoplasma contamination.</p><p>Cells were cultured on Geltrex-coated (0.2 mg/ml, Gibco, #A1413302) 6-well plates using 1× mTeSRTM-1 medium. Passaging was performed following dissociation with TrypLE Express enzymatic digestion (Gibco by Life Technologies). Upon initial plating, cells were cultured in medium containing 3 µM Rho-kinase inhibitor (Y-27632, Abcam). The medium was completely refreshed every day. Cells reaching 70% confluence were either passaged or cryopreserved in Stem Cell Freezing Media (mFreSR, StemCells, Catalog # 05854).</p></sec><sec id="s4-3"><title>Myeloid progenitor cell differentiation and microglial cell maturation</title><p>The protocol for the differentiation of hiPSC cells to myeloid progenitors and then to microglia were adapted and modified from those described previously by the Cowley laboratory (<xref ref-type="bibr" rid="bib79">van Wilgenburg et al., 2013</xref>; <xref ref-type="bibr" rid="bib30">Haenseler et al., 2017</xref>). The first step of the protocol to enable EB formation employed the Spin-EBs formation method performed in AggreWellsTM800 microwell culture plates (Stemcell Technologies, Catalog # 34825). Briefly, 1 ml of mTeSRTM-1 spin-EB medium was added into each culture well and centrifuged at 3000 × <italic>g</italic> for 2 min. Subsequently, 4 × 10<sup>6</sup> iPSCs in 1 ml of medium were added to the well of spin-EB plate and then centrifuged at 800 rpm for 3 min. The plate was incubated at 37°C, 5% CO<sub>2</sub> for 4 days, then 1 ml medium was replaced in a drop-wise manner every day for the next 4 days with an EB medium: mTeSR1 medium (STEMCELL Technologies) containing 50 ng/ml BMP-4 (Gibco- PHC9534), 20 ng/ml human stem cell factor (SCF, Miltenyi Biotec), and 50 ng/ml vascular endothelial growth factor (hVEGF, Gibco- PHC9394).</p><p>In the second step of myeloid progenitor differentiation, the resulting EBs were harvested with a 40-µm filter column. Approximately 150–200 EBs were transferred into a 75-cm<sup>2</sup> flask containing myeloid cell differentiation medium: TheraPEAK X-VIVO-15 Serum-free Hematopoietic Cell Medium (Lonza, Cat#: BEBP04-744Q) containing 100 ng/ml M-CSF (Invitrogen), 25 ng/ml IL-3 (R&amp;D), 2 mM Glutamax supplement (Invitrogen), 1× N2 supplement (Thermo Fisher Scientific, Cat#17502048). Two-thirds of the media volume in the culture flask was replaced every 5 days for 2–3 weeks.</p><p>In the third step of microglia differentiation, the non-adherent floating cell layer consisting of differentiated myeloid progenitor cells was harvested from the supernatant and transferred into the 6-well plate and allowed to settle and adhere overnight. Two-thirds of the medium volume was removed and replaced with a microglia cell differentiation medium: DMEM/F12 medium (Gibco, #11330) containing 50 ng/ml M-CSF (Invitrogen), 100 ng/ml IL-34 (Peprotech), 10 ng/ml TGFb1 and 2–5 ng/ml TGFb2 (both from R&amp;D Systems), 20 ng/ml CX3CL1 (Peprotech), 1× N2 supplement and 2 mM Glutamax supplement. The culture was maintained for 2 weeks after which the differentiated iPSC-derived microglia were harvested for analysis or for cell transplantation.</p></sec><sec id="s4-4"><title>Phagocytosis assay</title><p>To assess microglia phagocytosis in vitro, the following bioparticles were employed as targets: (1) pHrodo Red <italic>E. coli</italic> BioParticles Conjugate for Phagocytosis (Thermo Fisher Scientific, Cat#P35361); (2) pHrodo Red Zymosan Bioparticles Conjugate for Phagocytosis (Thermo Fisher Scientific, Cat#P35364); (3) bovine rod POSs (Invision Bioresources, Cat#98740). Bovine POS was diluted in serum-free DMEM/F12 (1:1; Gibco) to a concentration of 10<sup>6</sup> segments/ml and fluorescently labeled with the lipophilic dye DiI (Vybrant Cell-Labeling Solutions; Invitrogen) according to the manufacturer’s instructions. Each phagocytosis assay employed 1 × 10<sup>5</sup> POSs and 2 mg/ml pHrodo Red <italic>E. coli</italic> membrane/Zymosan BioParticles.</p><p>For the assay, harvested floating myeloid cells were transferred into 4-well chamber slides (Thermo Fisher). For phagocytosis assessment of myeloid cells, the cells were cultured for 1 day and challenged with bioparticles. To assess iPSC-derived microglia, the cells were cultured in a microglia cell differentiation medium for 2 weeks and then challenged. In the assay, bioparticles were added to the 100 µl serum-free DMEM/F12 medium in the slide chamber, incubated for 1 hr at 37°C, washed three times with phosphate-buffered saline (PBS), and then fixed in 4% paraformaldehyde (PFA) for 20 min. Fixed cells were immunostained with antibodies to IBA1 and P2RY12 and counterstained with DAPI. Stained cells were imaged with an Olympus 1000 confocal microscope, and image analysis was conducted using ImageJ software (NIH).</p></sec><sec id="s4-5"><title>mRNA and protein analysis following LPS challenge in vitro</title><p>Differentiated hiPSC-derived microglia cultured in 6-well plates were stimulated with LPS at 100 ng/ml for 6 and 24 hr. Microglia stimulated for 6 hr were collected in RNAlater solution (Thermo Fisher) and stored at −80°C for further qRT-PCR analysis. Microglia stimulated for 24 hr were collected for protein quantification. After the medium was collected, the cells in the well were washed with 1× PBS, and then 200 µl of RIPA lysis buffer with proteinase inhibitor cocktail (Calbiochem) was added; the cells were removed by scraping, collected into 1.5 ml Eppendorf tube, and then homogenized with sonication (Sonicator 125 Watts, Qsonica) at 4°C. After sonication and centrifugation, total protein concentration was measured (BCA protein assay kit; Pierce). Levels of individual cytokines were determined using a Milliplex bead assay kit (Milliplex MAP human cytokine/chemokine magnetic bead panel, #MCYTOMAG-70K; Millipore) and involving the Luminex MAPIX system with data analysis using xPONENT 4.2 software (Luminex). The cytokines analyzed included <italic>IL1A</italic>, <italic>IL1B</italic>, <italic>IL6</italic>, <italic>IL8</italic>, <italic>TNFa</italic>, <italic>CXCL10</italic>, <italic>CCL2</italic>, <italic>CCL3</italic>, <italic>CCL4</italic>, and <italic>IL10</italic>.</p></sec><sec id="s4-6"><title>mRNA expression analysis by quantitative RT-PCR</title><p>mRNA expression was quantitated using qRT-PCR. Harvested cells were lysed by trituration and homogenized using QIAshredder spin columns (QIAGEN). Total RNA was isolated using the RNeasy Mini kit (QIAGEN) according to the manufacturer’s specifications. First-strand cDNA synthesis from mRNA was performed using qScript cDNA SuperMix (Quanta Biosciences) using oligo-dT as primer. qRT-PCR was performed using an SYBR green RT-PCR kit (Affymetrix), using the Bio-Rad CFX96 Touch Real-Time PCR Detection System under the following conditions: denaturation at 95°C for 5 min, followed by 40 cycles of 95°C for 10 s, and then 60°C for 45 s. Threshold cycle (CT) values were calculated and expressed as fold-induction determined using the comparative CT (2ΔΔCT) method. Ribosomal protein S13 (RPS13) and GAPDH were used as internal controls. Oligonucleotide primers are provided in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>.</p></sec><sec id="s4-7"><title>Transplantation of hiPSC-derived microglia by subretinal injection</title><p>Differentiated hiPSC-derived microglia grown in flasks were first washed in 1× PBS before being removed by scraping and collected into a 50-ml tube in 5 ml PBS. Cell numbers were counted using a cell counter (Countess 3, Thermo Fisher). Microglia were collected by centrifugation (5 min at 4°C, 200 × <italic>g</italic>) and the resulting cell pellet resuspended in 1× PBS at a concentration of 5000 cells/µl for in vivo transplantation via subretinal injection. Experimental animals were given general anesthesia (ketamine 90 mg/kg and xylazine 8 mg/kg) and additional topical anesthesia (0.5% Proparacaine HCL, Sandoz) applied to the injected eye. For the injection, the temporal sclera was exposed by a conjunctival cut-down and a scleral incision made 0.5 mm behind the limbus using 32 G needle to access the subretinal space. The tip of a blunt 32 G needle attached to a Hamilton micro-syringe was introduced through the incision at an angle 5 degrees tangent to the globe and advanced 0.5–1 mm into the subretinal space under a dissecting microscope. Microglial cells (5000 cells in 1 µl PBS) were slowly injected from the micro-syringe into the subretinal space using an aseptic technique. Post-procedure, treated eyes were carefully inspected for signs of bleeding or distention and intraocular pressure was monitored using a tonometer (iCare TONOLAB, Finland). In the event that intraocular pressure remained elevated (&gt;20 mmHg) and/or the globe appeared distended, a vitreous tap was performed using a 33 G needle to reduce intraocular pressure. In the unlikely event that excessive bleeding is observed, the animal will be examined by a veterinarian or euthanized immediately.</p></sec><sec id="s4-8"><title>Immunohistochemical analyses</title><p>For immunohistochemical analysis of microglia in vitro, microglia were differentiated in 4-well chambered slides, fixed in 4% PFA for 20 min and processed for immunostaining. For in vivo analyses, recipient animals were euthanized by CO<sub>2</sub> inhalation, and the eyes were enucleated. Enucleated eyes were dissected to form posterior segment eyecups and fixed in 4% PFA in phosphate buffer (PB) for 2 hr at 4°C. Eyecups were either cryosectioned (Leica CM3050S) or further dissected to form retinal flat mounts. Flat-mounted retinas were blocked for 1 hr in a blocking buffer containing 10% normal donkey serum and 1% Triton X-100 in PBS at room temperature. Primary antibodies included IBA1 (1:500, Wako, #019-19741), anti-mouse Tmem119 (1:500, Synaptic Systems, #400 004), anti-human TMEM119 (1:100, Sigma, #HPA051870), anti-mouse Cd68 (1:200, Bio-Rad, #MCA1957), anti-human CD68 (1:100, R&amp;D, #MAB20401), anti-mouse Cd45 (1:100, Bio-Rad, #MCA1388), anti-human CD45 (1:100, R&amp;D, #FAB1430R), cone arrestin (1:200, Millipore, #AB15282), Ki67 (1:30, eBioscience, #50-5698-82), anti-P2RY12 (1:100, Thermo Fisher, #PA5-77671 and Sigma, #HPA014518), CD34 (1:50, eBioscience, #14–0341), hCD11b (1:100, R&amp;D, #FAB1699R), mCD11b (Bio-Rad, Cat#: MCA711G, 1:100), CX3CR1 (1:100, Invitrogen, #61-6099-42), hHLA (Invitrogen, #11-9983-42), SPI1 (Invitrogen, #MA5-15064), TREM2 (1:100, Invitrogen, #702886), glutamine synthetase (1:200, Millipore, #MAB302), PKCa (1:200, Sigma-Aldrich, #p4334), GFAP (1:200, Invitrogen, #13-0300), RBPMS (1:100, Phosphosolutions, 1832-RBPMS), Calbindin (1:5000, Swant, CB-38a), and anti-RFP (1:200, RockLand, 600-401-379-RTU). Primary antibodies were diluted in blocking buffer and incubated at 4°C overnight for retinal sections and at room temperature overnight on a shaker for retinal flat mounts. Experiments in which primary antibodies were omitted served as negative controls. After washing in 1× PBST (0.2% Tween-20 in PBS), retinal samples were incubated for 2 hr at room temperature with secondary antibodies (AlexaFluor 488-, 568-, or 647-conjugated anti-rabbit, mouse, rat, goat, and guinea pig IgG) and DAPI (1:500; Sigma-Aldrich) to label cell nuclei. Isolectin B4 (IB4), conjugated to AlexaFluor 568/647 (1:100, Life Technologies), was used to label activated microglia and retinal vessels. Stained retinal samples were imaged with confocal microscopy (Olympus FluoView 1000, or Zeiss LSM 880, or Nikon A1R). For analysis at high magnification, multiplane z-series were collected using 20 or 40 objectives; Confocal image stacks were viewed and analyzed with FV100 Viewer Software, NIS-Element Analysis and ImageJ (NIH).</p></sec><sec id="s4-9"><title>RNAseq analysis</title><p>For whole transcriptome analysis, cultured myeloid progenitor cells and differentiated microglial cells with and without 0.1 µg/ml LPS treatment were harvested in the flasks and 6-well plates, respectively. After harvesting, all samples stored frozen in RNAlater (Roche) solution before RNA extraction using the QIAGEN RNA Mini Kit. RNA quality and quantity were evaluated using Bioanalyzer 2100 with the RNA 6000 Nano Kit (Agilent Technologies). The preparation of RNA library and transcriptome sequencing was performed using an external vendor (Novogene, Sacramento, CA). Genes with adjusted p-value &lt;0.05 and log2FC (Fold Change) &gt;1 were considered differentially expressed. IPA (QIAGEN) was employed for canonical pathway and graphical pathway analysis. The microglia gene list was constructed from our previous microarray data from retinal microglial cells and published data (<xref ref-type="bibr" rid="bib48">Ma et al., 2013</xref>; <xref ref-type="bibr" rid="bib4">Bennett et al., 2016</xref>). The heat map, volcano, and histogram plot were performed using Prism 9.5.1 (GraphPad).</p></sec><sec id="s4-10"><title>NaIO<sub>3</sub>-induced model of RPE cell injury</title><p>Recipient mice 8 months following xenotransplantation were administered a single dose of NaIO<sub>3</sub> (Honeywell Research Chemicals) at a dose of 30 mg/kg body weight via intraperitoneal injection. Animals were euthanized 3 and 7 days after NaIO<sub>3</sub> injection, and their retinas were harvested and subjected to histological and molecular analysis.</p></sec><sec id="s4-11"><title>Statistics and reproducibility</title><p>All data in the graphical panel represent mean ± standard error. When only two independent groups were compared, signiﬁcance was determined by a two-tailed unpaired <italic>t</italic>-test with Welch’s correction. When three or more groups were compared, one-way ANOVA with the Bonferroni post hoc test or two-way ANOVA was used. A p-value &lt;0.05 was considered signiﬁcant. The analyses were done in GraphPad Prism v.5. All experiments were independently performed at least three experimental replicates to confirm consistency in observations across replicates.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation</p></fn><fn fn-type="con" id="con4"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Supervision</p></fn><fn fn-type="con" id="con6"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Visualization, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved Institutional Animal Care and Use Committee (IACUC) protocols (#NEI-698) of approved by the Institutional Animal Care and Use Committee (National Eye Institute Animal Care and Use Committee) and adhered to the Association for Research in Vision and Ophthalmology (ARVO) statement on animal use in ophthalmic and vision research. All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Microglia-enriched gene list.</title><p>The gene list of 71 microglia-enriched genes was extracted from bulk RNAseq of microglial cells vs. myeloid progenitor cells (MPCs). The total microglia-enriched gene list combined from the research conducted by Barres BA Lab (Bennett et al., Proc Natl Acad Sci U S A, 2016) and from our RNA sequencing data of mouse retinal microglia (<xref ref-type="bibr" rid="bib48">Ma et al., 2013</xref>), identifying a total of 130 genes predominantly expressed in microglia.</p></caption><media xlink:href="elife-90695-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>188 hMG gene comparisons vs. GSE178846.</title><p>The human microglia gene panel combined our mouse microglia-enriched genes and human microglia-enriched genes (<xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>; <xref ref-type="bibr" rid="bib51">Muffat et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Douvaras et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Böttcher et al., 2019</xref>; <xref ref-type="bibr" rid="bib78">van der Poel et al., 2019</xref>). The total microglia-enriched gene list contains 203 genes, which used to be extracted from the gene profile of hiPSC-MG and downloaded human adult microglia (AMG), fetal microglia (FMG), inflammatory monocyte (IM) and monocytes (M) (GSE 178846, <xref ref-type="bibr" rid="bib1">Abud et al., 2017</xref>). 188 genes were obtained from both gene lists. All the gene counts were normalized with four human cells housekeeping genes C1orf43, RAB7A, REEP5, and VCP (<xref ref-type="bibr" rid="bib21">Eisenberg and Levanon, 2013</xref>).</p></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-90695-supp2-v1.xls"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>The gene list of comparison vs. GSE111972.</title><p>The total gene list of both male and female hiPSC-derived microglial cells and human brain microglia cells (GSE 111972, <xref ref-type="bibr" rid="bib78">van der Poel et al., 2019</xref>).</p></caption><media xlink:href="elife-90695-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>The oligos for quantitative reverse transcription-PCR (qRT-PCR).</title><p>The oligos were used for qRT-PCR in cultured hiPSC-derived cells.</p></caption><media xlink:href="elife-90695-supp4-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Human-specific oligos for quantitative reverse transcription-PCR (qRT-PCR).</title><p>The oligos were used for qRT-PCR in mouse retinas with integrated hiPSC-derived microglial cells.</p></caption><media xlink:href="elife-90695-supp5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>42 genes associated with age-related macular degeneration (AMD).</title><p>42 candidate genes from 34 loci associated with AMD expressed in retinal microglia cells. The microglia gene expression data are from microarray data previously published (<xref ref-type="bibr" rid="bib48">Ma et al., 2013</xref>). The candidate genes came from the published paper (<xref ref-type="bibr" rid="bib19">den Hollander et al., 2022</xref>).</p></caption><media xlink:href="elife-90695-supp6-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>209 genes associated with age-related macular degeneration (AMD).</title><p>The 209 microglia-enriched genes were extracted from the genes associated with AMD (<xref ref-type="bibr" rid="bib24">Fritsche et al., 2016</xref>). The microglia gene expression data are from microarray data previously published (<xref ref-type="bibr" rid="bib48">Ma et al., 2013</xref>).</p></caption><media xlink:href="elife-90695-supp7-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-90695-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files; source data files have been provided for Figures 2 and 3 and Figure 2 suppl. A, B, and C.</p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Abud</surname><given-names>EM</given-names></name><name><surname>Ramirez</surname><given-names>RN</given-names></name><name><surname>Martinez</surname><given-names>ES</given-names></name><name><surname>Healy</surname><given-names>LM</given-names></name><name><surname>Nguyen</surname><given-names>CHH</given-names></name><name><surname>Newman</surname><given-names>SA</given-names></name><name><surname>Yeromin</surname><given-names>AV</given-names></name><name><surname>Scarfone</surname><given-names>VM</given-names></name><name><surname>Marsh</surname><given-names>SE</given-names></name><name><surname>Fimbres</surname><given-names>C</given-names></name><name><surname>Caraway</surname><given-names>CA</given-names></name><name><surname>Fote</surname><given-names>GM</given-names></name><name><surname>Madany</surname><given-names>AM</given-names></name><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Gylys</surname><given-names>KH</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name><name><surname>Cummings</surname><given-names>BJ</given-names></name><name><surname>Antel</surname><given-names>JP</given-names></name><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Carson</surname><given-names>MJ</given-names></name><name><surname>Poon</surname><given-names>WW</given-names></name><name><surname>Blurton-Jones</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Generation of human microglia-like cells to study neurological disease</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89189">GSE89189</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>an der Poel</surname><given-names>M</given-names></name><name><surname>Ulas</surname><given-names>T</given-names></name><name><surname>Mizee</surname><given-names>MR</given-names></name><name><surname>Hsiao</surname><given-names>CC</given-names></name><name><surname>Miedema</surname><given-names>SSM</given-names></name><name><surname>Adelia</surname><given-names>SKG</given-names></name><name><surname>Helder</surname><given-names>B</given-names></name><name><surname>Tas</surname><given-names>SW</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Hamann</surname><given-names>J</given-names></name><name><surname>Huitinga</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Transcriptional profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-associated changes</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111972">GSE111972</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This study was supported by the National Eye Institute Intramural Research program.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abud</surname><given-names>EM</given-names></name><name><surname>Ramirez</surname><given-names>RN</given-names></name><name><surname>Martinez</surname><given-names>ES</given-names></name><name><surname>Healy</surname><given-names>LM</given-names></name><name><surname>Nguyen</surname><given-names>CHH</given-names></name><name><surname>Newman</surname><given-names>SA</given-names></name><name><surname>Yeromin</surname><given-names>AV</given-names></name><name><surname>Scarfone</surname><given-names>VM</given-names></name><name><surname>Marsh</surname><given-names>SE</given-names></name><name><surname>Fimbres</surname><given-names>C</given-names></name><name><surname>Caraway</surname><given-names>CA</given-names></name><name><surname>Fote</surname><given-names>GM</given-names></name><name><surname>Madany</surname><given-names>AM</given-names></name><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Gylys</surname><given-names>KH</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name><name><surname>Cummings</surname><given-names>BJ</given-names></name><name><surname>Antel</surname><given-names>JP</given-names></name><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Carson</surname><given-names>MJ</given-names></name><name><surname>Poon</surname><given-names>WW</given-names></name><name><surname>Blurton-Jones</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases</article-title><source>Neuron</source><volume>94</volume><fpage>278</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.03.042</pub-id><pub-id pub-id-type="pmid">28426964</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>SR</given-names></name><name><surname>Roberts</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Steele</surname><given-names>MR</given-names></name><name><surname>Romero</surname><given-names>CO</given-names></name><name><surname>Bosco</surname><given-names>A</given-names></name><name><surname>Vetter</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Developmental Apoptosis Promotes a Disease-Related Gene Signature and Independence from CSF1R Signaling in Retinal Microglia</article-title><source>Cell Reports</source><volume>27</volume><fpage>2002</fpage><lpage>2013</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.04.062</pub-id><pub-id pub-id-type="pmid">31091440</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname><given-names>NPB</given-names></name><name><surname>Ma</surname><given-names>CHE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Neuroinflammation, microglia and implications for retinal ganglion cell survival and axon regeneration in traumatic optic neuropathy</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>860070</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.860070</pub-id><pub-id pub-id-type="pmid">35309305</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>ML</given-names></name><name><surname>Bennett</surname><given-names>FC</given-names></name><name><surname>Liddelow</surname><given-names>SA</given-names></name><name><surname>Ajami</surname><given-names>B</given-names></name><name><surname>Zamanian</surname><given-names>JL</given-names></name><name><surname>Fernhoff</surname><given-names>NB</given-names></name><name><surname>Mulinyawe</surname><given-names>SB</given-names></name><name><surname>Bohlen</surname><given-names>CJ</given-names></name><name><surname>Adil</surname><given-names>A</given-names></name><name><surname>Tucker</surname><given-names>A</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Chang</surname><given-names>EF</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Grant</surname><given-names>GA</given-names></name><name><surname>Hayden Gephart</surname><given-names>MG</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>New tools for studying microglia in the mouse and human CNS</article-title><source>PNAS</source><volume>113</volume><fpage>E1738</fpage><lpage>E1746</lpage><pub-id pub-id-type="doi">10.1073/pnas.1525528113</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beutner</surname><given-names>C</given-names></name><name><surname>Lepperhof</surname><given-names>V</given-names></name><name><surname>Dann</surname><given-names>A</given-names></name><name><surname>Linnartz-Gerlach</surname><given-names>B</given-names></name><name><surname>Litwak</surname><given-names>S</given-names></name><name><surname>Napoli</surname><given-names>I</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Engineered stem cell-derived microglia as therapeutic vehicle for experimental autoimmune encephalomyelitis</article-title><source>Gene Therapy</source><volume>20</volume><fpage>797</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1038/gt.2012.100</pub-id><pub-id pub-id-type="pmid">23324824</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohlen</surname><given-names>CJ</given-names></name><name><surname>Bennett</surname><given-names>FC</given-names></name><name><surname>Tucker</surname><given-names>AF</given-names></name><name><surname>Collins</surname><given-names>HY</given-names></name><name><surname>Mulinyawe</surname><given-names>SB</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>DIverse requirements for microglial survival, specification, and function revealed by defined-medium cultures</article-title><source>Neuron</source><volume>94</volume><fpage>759</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.04.043</pub-id><pub-id pub-id-type="pmid">28521131</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosco</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>SR</given-names></name><name><surname>Roberts</surname><given-names>JM</given-names></name><name><surname>Romero</surname><given-names>CO</given-names></name><name><surname>Steele</surname><given-names>MR</given-names></name><name><surname>Vetter</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Retinal microglia acquire a disease-associated transcriptome in chronic mouse glaucoma, which intensifies with neuroprotective complement inhibition</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>60</volume><elocation-id>4002</elocation-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Böttcher</surname><given-names>C</given-names></name><name><surname>Schlickeiser</surname><given-names>S</given-names></name><name><surname>Sneeboer</surname><given-names>MAM</given-names></name><name><surname>Kunkel</surname><given-names>D</given-names></name><name><surname>Knop</surname><given-names>A</given-names></name><name><surname>Paza</surname><given-names>E</given-names></name><name><surname>Fidzinski</surname><given-names>P</given-names></name><name><surname>Kraus</surname><given-names>L</given-names></name><name><surname>Snijders</surname><given-names>GJL</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name><name><surname>Schulz</surname><given-names>AR</given-names></name><name><surname>Mei</surname><given-names>HE</given-names></name><name><surname>Hol</surname><given-names>EM</given-names></name><name><surname>Siegmund</surname><given-names>B</given-names></name><name><surname>Glauben</surname><given-names>R</given-names></name><name><surname>Spruth</surname><given-names>EJ</given-names></name><name><surname>de Witte</surname><given-names>LD</given-names></name><name><surname>Priller</surname><given-names>J</given-names></name><collab>NBB-Psy</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry</article-title><source>Nature Neuroscience</source><volume>22</volume><fpage>78</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/s41593-018-0290-2</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broderick</surname><given-names>C</given-names></name><name><surname>Hoek</surname><given-names>RM</given-names></name><name><surname>Forrester</surname><given-names>JV</given-names></name><name><surname>Liversidge</surname><given-names>J</given-names></name><name><surname>Sedgwick</surname><given-names>JD</given-names></name><name><surname>Dick</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis</article-title><source>The American Journal of Pathology</source><volume>161</volume><fpage>1669</fpage><lpage>1677</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)64444-6</pub-id><pub-id pub-id-type="pmid">12414514</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>TC</given-names></name><name><surname>Li</surname><given-names>MD</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Awad</surname><given-names>AJ</given-names></name><name><surname>Morgan</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mouse models rarely mimic the transcriptome of human neurodegenerative diseases: A systematic bioinformatics-based critique of preclinical models</article-title><source>European Journal of Pharmacology</source><volume>759</volume><fpage>101</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.03.021</pub-id><pub-id pub-id-type="pmid">25814260</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butovsky</surname><given-names>O</given-names></name><name><surname>Jedrychowski</surname><given-names>MP</given-names></name><name><surname>Moore</surname><given-names>CS</given-names></name><name><surname>Cialic</surname><given-names>R</given-names></name><name><surname>Lanser</surname><given-names>AJ</given-names></name><name><surname>Gabriely</surname><given-names>G</given-names></name><name><surname>Koeglsperger</surname><given-names>T</given-names></name><name><surname>Dake</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>PM</given-names></name><name><surname>Doykan</surname><given-names>CE</given-names></name><name><surname>Fanek</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Antel</surname><given-names>JP</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of a unique TGF-β-dependent molecular and functional signature in microglia</article-title><source>Nature Neuroscience</source><volume>17</volume><fpage>131</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/nn.3599</pub-id><pub-id pub-id-type="pmid">24316888</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadarevian</surname><given-names>JP</given-names></name><name><surname>Lombroso</surname><given-names>SI</given-names></name><name><surname>Peet</surname><given-names>GC</given-names></name><name><surname>Hasselmann</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>C</given-names></name><name><surname>Marzan</surname><given-names>DE</given-names></name><name><surname>Capocchi</surname><given-names>J</given-names></name><name><surname>Purnell</surname><given-names>FS</given-names></name><name><surname>Nemec</surname><given-names>KM</given-names></name><name><surname>Lahian</surname><given-names>A</given-names></name><name><surname>Escobar</surname><given-names>A</given-names></name><name><surname>England</surname><given-names>W</given-names></name><name><surname>Chaluvadi</surname><given-names>S</given-names></name><name><surname>O’Brien</surname><given-names>CA</given-names></name><name><surname>Yaqoob</surname><given-names>F</given-names></name><name><surname>Aisenberg</surname><given-names>WH</given-names></name><name><surname>Porras-Paniagua</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>ML</given-names></name><name><surname>Davtyan</surname><given-names>H</given-names></name><name><surname>Spitale</surname><given-names>RC</given-names></name><name><surname>Blurton-Jones</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>FC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Engineering an inhibitor-resistant human CSF1R variant for microglia replacement</article-title><source>The Journal of Experimental Medicine</source><volume>220</volume><elocation-id>e20220857</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20220857</pub-id><pub-id pub-id-type="pmid">36584406</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Checchin</surname><given-names>D</given-names></name><name><surname>Sennlaub</surname><given-names>F</given-names></name><name><surname>Levavasseur</surname><given-names>E</given-names></name><name><surname>Leduc</surname><given-names>M</given-names></name><name><surname>Chemtob</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Potential role of microglia in retinal blood vessel formation</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>47</volume><fpage>3595</fpage><lpage>3602</lpage><pub-id pub-id-type="doi">10.1167/iovs.05-1522</pub-id><pub-id pub-id-type="pmid">16877434</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Butovsky</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Microglia function in the central nervous system during health and neurodegeneration</article-title><source>Annual Review of Immunology</source><volume>35</volume><fpage>441</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-051116-052358</pub-id><pub-id pub-id-type="pmid">28226226</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Combadière</surname><given-names>C</given-names></name><name><surname>Feumi</surname><given-names>C</given-names></name><name><surname>Raoul</surname><given-names>W</given-names></name><name><surname>Keller</surname><given-names>N</given-names></name><name><surname>Rodéro</surname><given-names>M</given-names></name><name><surname>Pézard</surname><given-names>A</given-names></name><name><surname>Lavalette</surname><given-names>S</given-names></name><name><surname>Houssier</surname><given-names>M</given-names></name><name><surname>Jonet</surname><given-names>L</given-names></name><name><surname>Picard</surname><given-names>E</given-names></name><name><surname>Debré</surname><given-names>P</given-names></name><name><surname>Sirinyan</surname><given-names>M</given-names></name><name><surname>Deterre</surname><given-names>P</given-names></name><name><surname>Ferroukhi</surname><given-names>T</given-names></name><name><surname>Cohen</surname><given-names>S-Y</given-names></name><name><surname>Chauvaud</surname><given-names>D</given-names></name><name><surname>Jeanny</surname><given-names>J-C</given-names></name><name><surname>Chemtob</surname><given-names>S</given-names></name><name><surname>Behar-Cohen</surname><given-names>F</given-names></name><name><surname>Sennlaub</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration</article-title><source>The Journal of Clinical Investigation</source><volume>117</volume><fpage>2920</fpage><lpage>2928</lpage><pub-id pub-id-type="doi">10.1172/JCI31692</pub-id><pub-id pub-id-type="pmid">17909628</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cukras</surname><given-names>CA</given-names></name><name><surname>Petrou</surname><given-names>P</given-names></name><name><surname>Chew</surname><given-names>EY</given-names></name><name><surname>Meyerle</surname><given-names>CB</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>53</volume><fpage>3865</fpage><lpage>3874</lpage><pub-id pub-id-type="doi">10.1167/iovs.11-9413</pub-id><pub-id pub-id-type="pmid">22589436</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagher</surname><given-names>NN</given-names></name><name><surname>Najafi</surname><given-names>AR</given-names></name><name><surname>Kayala</surname><given-names>KMN</given-names></name><name><surname>Elmore</surname><given-names>MRP</given-names></name><name><surname>White</surname><given-names>TE</given-names></name><name><surname>Medeiros</surname><given-names>R</given-names></name><name><surname>West</surname><given-names>BL</given-names></name><name><surname>Green</surname><given-names>KN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice</article-title><source>Journal of Neuroinflammation</source><volume>12</volume><elocation-id>139</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-015-0366-9</pub-id><pub-id pub-id-type="pmid">26232154</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Golde</surname><given-names>TE</given-names></name><name><surname>Lagier-Tourenne</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Animal models of neurodegenerative diseases</article-title><source>Nature Neuroscience</source><volume>21</volume><fpage>1370</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1038/s41593-018-0236-8</pub-id><pub-id pub-id-type="pmid">30250265</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>den Hollander</surname><given-names>AI</given-names></name><name><surname>Mullins</surname><given-names>RF</given-names></name><name><surname>Orozco</surname><given-names>LD</given-names></name><name><surname>Voigt</surname><given-names>AP</given-names></name><name><surname>Chen</surname><given-names>H-H</given-names></name><name><surname>Strunz</surname><given-names>T</given-names></name><name><surname>Grassmann</surname><given-names>F</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Kuiper</surname><given-names>JJW</given-names></name><name><surname>Tumminia</surname><given-names>SJ</given-names></name><name><surname>Allikmets</surname><given-names>R</given-names></name><name><surname>Hageman</surname><given-names>GS</given-names></name><name><surname>Stambolian</surname><given-names>D</given-names></name><name><surname>Klaver</surname><given-names>CCW</given-names></name><name><surname>Boeke</surname><given-names>JD</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Honigberg</surname><given-names>L</given-names></name><name><surname>Katti</surname><given-names>S</given-names></name><name><surname>Frazer</surname><given-names>KA</given-names></name><name><surname>Weber</surname><given-names>BHF</given-names></name><name><surname>Gorin</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Systems genomics in age-related macular degeneration</article-title><source>Experimental Eye Research</source><volume>225</volume><elocation-id>109248</elocation-id><pub-id pub-id-type="doi">10.1016/j.exer.2022.109248</pub-id><pub-id pub-id-type="pmid">36108770</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douvaras</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Kruglikov</surname><given-names>I</given-names></name><name><surname>Lallos</surname><given-names>G</given-names></name><name><surname>Zimmer</surname><given-names>M</given-names></name><name><surname>Terrenoire</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Gandy</surname><given-names>S</given-names></name><name><surname>Schadt</surname><given-names>E</given-names></name><name><surname>Freytes</surname><given-names>DO</given-names></name><name><surname>Noggle</surname><given-names>S</given-names></name><name><surname>Fossati</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Directed differentiation of human pluripotent stem cells to microglia</article-title><source>Stem Cell Reports</source><volume>8</volume><fpage>1516</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.04.023</pub-id><pub-id pub-id-type="pmid">28528700</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenberg</surname><given-names>E</given-names></name><name><surname>Levanon</surname><given-names>EY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Human housekeeping genes, revisited</article-title><source>Trends in Genetics</source><volume>29</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2013.05.010</pub-id><pub-id pub-id-type="pmid">23810203</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmore</surname><given-names>MRP</given-names></name><name><surname>Hohsfield</surname><given-names>LA</given-names></name><name><surname>Kramár</surname><given-names>EA</given-names></name><name><surname>Soreq</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Pham</surname><given-names>ST</given-names></name><name><surname>Najafi</surname><given-names>AR</given-names></name><name><surname>Spangenberg</surname><given-names>EE</given-names></name><name><surname>Wood</surname><given-names>MA</given-names></name><name><surname>West</surname><given-names>BL</given-names></name><name><surname>Green</surname><given-names>KN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Replacement of microglia in the aged brain reverses cognitive, synaptic, and neuronal deficits in mice</article-title><source>Aging Cell</source><volume>17</volume><elocation-id>e12832</elocation-id><pub-id pub-id-type="doi">10.1111/acel.12832</pub-id><pub-id pub-id-type="pmid">30276955</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>BA</given-names></name><name><surname>Srinivasan</surname><given-names>K</given-names></name><name><surname>Ayalon</surname><given-names>G</given-names></name><name><surname>Meilandt</surname><given-names>WJ</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Huntley</surname><given-names>MA</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>S-H</given-names></name><name><surname>Haddick</surname><given-names>PCG</given-names></name><name><surname>Ngu</surname><given-names>H</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Larson</surname><given-names>JL</given-names></name><name><surname>Kaminker</surname><given-names>JS</given-names></name><name><surname>van der Brug</surname><given-names>MP</given-names></name><name><surname>Hansen</surname><given-names>DV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of alzheimer’s disease not evident in mouse models</article-title><source>Cell Reports</source><volume>22</volume><fpage>832</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.12.066</pub-id><pub-id pub-id-type="pmid">29346778</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritsche</surname><given-names>LG</given-names></name><name><surname>Igl</surname><given-names>W</given-names></name><name><surname>Bailey</surname><given-names>JNC</given-names></name><name><surname>Grassmann</surname><given-names>F</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Bragg-Gresham</surname><given-names>JL</given-names></name><name><surname>Burdon</surname><given-names>KP</given-names></name><name><surname>Hebbring</surname><given-names>SJ</given-names></name><name><surname>Wen</surname><given-names>C</given-names></name><name><surname>Gorski</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>IK</given-names></name><name><surname>Cho</surname><given-names>D</given-names></name><name><surname>Zack</surname><given-names>D</given-names></name><name><surname>Souied</surname><given-names>E</given-names></name><name><surname>Scholl</surname><given-names>HPN</given-names></name><name><surname>Bala</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>KE</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Sardell</surname><given-names>RJ</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Merriam</surname><given-names>JE</given-names></name><name><surname>Cipriani</surname><given-names>V</given-names></name><name><surname>Hoffman</surname><given-names>JD</given-names></name><name><surname>Schick</surname><given-names>T</given-names></name><name><surname>Lechanteur</surname><given-names>YTE</given-names></name><name><surname>Guymer</surname><given-names>RH</given-names></name><name><surname>Johnson</surname><given-names>MP</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Stanton</surname><given-names>CM</given-names></name><name><surname>Buitendijk</surname><given-names>GHS</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name><name><surname>Kwong</surname><given-names>AM</given-names></name><name><surname>Boleda</surname><given-names>A</given-names></name><name><surname>Brooks</surname><given-names>M</given-names></name><name><surname>Gieser</surname><given-names>L</given-names></name><name><surname>Ratnapriya</surname><given-names>R</given-names></name><name><surname>Branham</surname><given-names>KE</given-names></name><name><surname>Foerster</surname><given-names>JR</given-names></name><name><surname>Heckenlively</surname><given-names>JR</given-names></name><name><surname>Othman</surname><given-names>MI</given-names></name><name><surname>Vote</surname><given-names>BJ</given-names></name><name><surname>Liang</surname><given-names>HH</given-names></name><name><surname>Souzeau</surname><given-names>E</given-names></name><name><surname>McAllister</surname><given-names>IL</given-names></name><name><surname>Isaacs</surname><given-names>T</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Lake</surname><given-names>S</given-names></name><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Constable</surname><given-names>IJ</given-names></name><name><surname>Craig</surname><given-names>JE</given-names></name><name><surname>Kitchner</surname><given-names>TE</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Ouyang</surname><given-names>H</given-names></name><name><surname>Flagg</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Mao</surname><given-names>G</given-names></name><name><surname>Ferreyra</surname><given-names>H</given-names></name><name><surname>Stark</surname><given-names>K</given-names></name><name><surname>von Strachwitz</surname><given-names>CN</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Brandl</surname><given-names>C</given-names></name><name><surname>Rudolph</surname><given-names>G</given-names></name><name><surname>Olden</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>MA</given-names></name><name><surname>Morgan</surname><given-names>DJ</given-names></name><name><surname>Schu</surname><given-names>M</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Tsironi</surname><given-names>EE</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name><name><surname>Orlin</surname><given-names>A</given-names></name><name><surname>Brucker</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Curcio</surname><given-names>CA</given-names></name><name><surname>Mohand-Saïd</surname><given-names>S</given-names></name><name><surname>Sahel</surname><given-names>J-A</given-names></name><name><surname>Audo</surname><given-names>I</given-names></name><name><surname>Benchaboune</surname><given-names>M</given-names></name><name><surname>Cree</surname><given-names>AJ</given-names></name><name><surname>Rennie</surname><given-names>CA</given-names></name><name><surname>Goverdhan</surname><given-names>SV</given-names></name><name><surname>Grunin</surname><given-names>M</given-names></name><name><surname>Hagbi-Levi</surname><given-names>S</given-names></name><name><surname>Campochiaro</surname><given-names>P</given-names></name><name><surname>Katsanis</surname><given-names>N</given-names></name><name><surname>Holz</surname><given-names>FG</given-names></name><name><surname>Blond</surname><given-names>F</given-names></name><name><surname>Blanché</surname><given-names>H</given-names></name><name><surname>Deleuze</surname><given-names>J-F</given-names></name><name><surname>Igo</surname><given-names>RP</given-names><suffix>Jr</suffix></name><name><surname>Truitt</surname><given-names>B</given-names></name><name><surname>Peachey</surname><given-names>NS</given-names></name><name><surname>Meuer</surname><given-names>SM</given-names></name><name><surname>Myers</surname><given-names>CE</given-names></name><name><surname>Moore</surname><given-names>EL</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Hauser</surname><given-names>MA</given-names></name><name><surname>Postel</surname><given-names>EA</given-names></name><name><surname>Courtenay</surname><given-names>MD</given-names></name><name><surname>Schwartz</surname><given-names>SG</given-names></name><name><surname>Kovach</surname><given-names>JL</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Liew</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>AG</given-names></name><name><surname>Gopinath</surname><given-names>B</given-names></name><name><surname>Merriam</surname><given-names>JC</given-names></name><name><surname>Smith</surname><given-names>RT</given-names></name><name><surname>Khan</surname><given-names>JC</given-names></name><name><surname>Shahid</surname><given-names>H</given-names></name><name><surname>Moore</surname><given-names>AT</given-names></name><name><surname>McGrath</surname><given-names>JA</given-names></name><name><surname>Laux</surname><given-names>R</given-names></name><name><surname>Brantley</surname><given-names>MA</given-names><suffix>Jr</suffix></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Ersoy</surname><given-names>L</given-names></name><name><surname>Caramoy</surname><given-names>A</given-names></name><name><surname>Langmann</surname><given-names>T</given-names></name><name><surname>Saksens</surname><given-names>NTM</given-names></name><name><surname>de Jong</surname><given-names>EK</given-names></name><name><surname>Hoyng</surname><given-names>CB</given-names></name><name><surname>Cain</surname><given-names>MS</given-names></name><name><surname>Richardson</surname><given-names>AJ</given-names></name><name><surname>Martin</surname><given-names>TM</given-names></name><name><surname>Blangero</surname><given-names>J</given-names></name><name><surname>Weeks</surname><given-names>DE</given-names></name><name><surname>Dhillon</surname><given-names>B</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Doheny</surname><given-names>KF</given-names></name><name><surname>Romm</surname><given-names>J</given-names></name><name><surname>Klaver</surname><given-names>CCW</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Gorin</surname><given-names>MB</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name><name><surname>Baird</surname><given-names>PN</given-names></name><name><surname>den Hollander</surname><given-names>AI</given-names></name><name><surname>Fauser</surname><given-names>S</given-names></name><name><surname>Yates</surname><given-names>JRW</given-names></name><name><surname>Allikmets</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Schaumberg</surname><given-names>DA</given-names></name><name><surname>Klein</surname><given-names>BEK</given-names></name><name><surname>Hagstrom</surname><given-names>SA</given-names></name><name><surname>Chowers</surname><given-names>I</given-names></name><name><surname>Lotery</surname><given-names>AJ</given-names></name><name><surname>Léveillard</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Brilliant</surname><given-names>MH</given-names></name><name><surname>Hewitt</surname><given-names>AW</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Chew</surname><given-names>EY</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>DeAngelis</surname><given-names>M</given-names></name><name><surname>Stambolian</surname><given-names>D</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Iyengar</surname><given-names>SK</given-names></name><name><surname>Weber</surname><given-names>BHF</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Heid</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants</article-title><source>Nature Genetics</source><volume>48</volume><fpage>134</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/ng.3448</pub-id><pub-id pub-id-type="pmid">26691988</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galatro</surname><given-names>TF</given-names></name><name><surname>Holtman</surname><given-names>IR</given-names></name><name><surname>Lerario</surname><given-names>AM</given-names></name><name><surname>Vainchtein</surname><given-names>ID</given-names></name><name><surname>Brouwer</surname><given-names>N</given-names></name><name><surname>Sola</surname><given-names>PR</given-names></name><name><surname>Veras</surname><given-names>MM</given-names></name><name><surname>Pereira</surname><given-names>TF</given-names></name><name><surname>Leite</surname><given-names>REP</given-names></name><name><surname>Möller</surname><given-names>T</given-names></name><name><surname>Wes</surname><given-names>PD</given-names></name><name><surname>Sogayar</surname><given-names>MC</given-names></name><name><surname>Laman</surname><given-names>JD</given-names></name><name><surname>den Dunnen</surname><given-names>W</given-names></name><name><surname>Pasqualucci</surname><given-names>CA</given-names></name><name><surname>Oba-Shinjo</surname><given-names>SM</given-names></name><name><surname>Boddeke</surname><given-names>EWGM</given-names></name><name><surname>Marie</surname><given-names>SKN</given-names></name><name><surname>Eggen</surname><given-names>BJL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcriptomic analysis of purified human cortical microglia reveals age-associated changes</article-title><source>Nature Neuroscience</source><volume>20</volume><fpage>1162</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1038/nn.4597</pub-id><pub-id pub-id-type="pmid">28671693</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosselin</surname><given-names>D</given-names></name><name><surname>Skola</surname><given-names>D</given-names></name><name><surname>Coufal</surname><given-names>NG</given-names></name><name><surname>Holtman</surname><given-names>IR</given-names></name><name><surname>Schlachetzki</surname><given-names>JCM</given-names></name><name><surname>Sajti</surname><given-names>E</given-names></name><name><surname>Jaeger</surname><given-names>BN</given-names></name><name><surname>O’Connor</surname><given-names>C</given-names></name><name><surname>Fitzpatrick</surname><given-names>C</given-names></name><name><surname>Pasillas</surname><given-names>MP</given-names></name><name><surname>Pena</surname><given-names>M</given-names></name><name><surname>Adair</surname><given-names>A</given-names></name><name><surname>Gonda</surname><given-names>DD</given-names></name><name><surname>Levy</surname><given-names>ML</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An environment-dependent transcriptional network specifies human microglia identity</article-title><source>Science</source><volume>356</volume><elocation-id>eaal3222</elocation-id><pub-id pub-id-type="doi">10.1126/science.aal3222</pub-id><pub-id pub-id-type="pmid">28546318</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Oguin</surname><given-names>TH</given-names></name><name><surname>Martinez</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The clearance of dying cells: table for two</article-title><source>Cell Death and Differentiation</source><volume>23</volume><fpage>915</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1038/cdd.2015.172</pub-id><pub-id pub-id-type="pmid">26990661</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilliams</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Does niche competition determine the origin of tissue-resident macrophages?</article-title><source>Nature Reviews. Immunology</source><volume>17</volume><fpage>451</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.42</pub-id><pub-id pub-id-type="pmid">28461703</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Cázarez-Márquez</surname><given-names>F</given-names></name><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Foppen</surname><given-names>E</given-names></name><name><surname>Korpel</surname><given-names>NL</given-names></name><name><surname>Grootemaat</surname><given-names>AE</given-names></name><name><surname>Liv</surname><given-names>N</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>van der Wel</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Nie</surname><given-names>G</given-names></name><name><surname>Yi</surname><given-names>C-X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Specific Silencing of Microglial Gene Expression in the Rat Brain by Nanoparticle-Based Small Interfering RNA Delivery</article-title><source>ACS Applied Materials &amp; Interfaces</source><volume>14</volume><fpage>5066</fpage><lpage>5079</lpage><pub-id pub-id-type="doi">10.1021/acsami.1c22434</pub-id><pub-id pub-id-type="pmid">35041392</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haenseler</surname><given-names>W</given-names></name><name><surname>Sansom</surname><given-names>SN</given-names></name><name><surname>Buchrieser</surname><given-names>J</given-names></name><name><surname>Newey</surname><given-names>SE</given-names></name><name><surname>Moore</surname><given-names>CS</given-names></name><name><surname>Nicholls</surname><given-names>FJ</given-names></name><name><surname>Chintawar</surname><given-names>S</given-names></name><name><surname>Schnell</surname><given-names>C</given-names></name><name><surname>Antel</surname><given-names>JP</given-names></name><name><surname>Allen</surname><given-names>ND</given-names></name><name><surname>Cader</surname><given-names>MZ</given-names></name><name><surname>Wade-Martins</surname><given-names>R</given-names></name><name><surname>James</surname><given-names>WS</given-names></name><name><surname>Cowley</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A highly efficient human pluripotent stem cell microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response</article-title><source>Stem Cell Reports</source><volume>8</volume><fpage>1727</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.05.017</pub-id><pub-id pub-id-type="pmid">28591653</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Sarlus</surname><given-names>H</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Karrenbauer</surname><given-names>VD</given-names></name><name><surname>Harris</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Microglial replacement therapy: a potential therapeutic strategy for incurable CSF1R-related leukoencephalopathy</article-title><source>Acta Neuropathologica Communications</source><volume>8</volume><elocation-id>217</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-020-01093-3</pub-id><pub-id pub-id-type="pmid">33287883</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasselmann</surname><given-names>J</given-names></name><name><surname>Blurton-Jones</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human iPSC-derived microglia: A growing toolset to study the brain’s innate immune cells</article-title><source>Glia</source><volume>68</volume><fpage>721</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1002/glia.23781</pub-id><pub-id pub-id-type="pmid">31926038</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hohsfield</surname><given-names>LA</given-names></name><name><surname>Najafi</surname><given-names>AR</given-names></name><name><surname>Ghorbanian</surname><given-names>Y</given-names></name><name><surname>Soni</surname><given-names>N</given-names></name><name><surname>Hingco</surname><given-names>EE</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Jue</surname><given-names>AD</given-names></name><name><surname>Swarup</surname><given-names>V</given-names></name><name><surname>Inlay</surname><given-names>MA</given-names></name><name><surname>Green</surname><given-names>KN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Effects of long-term and brain-wide colonization of peripheral bone marrow-derived myeloid cells in the CNS</article-title><source>Journal of Neuroinflammation</source><volume>17</volume><elocation-id>279</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-020-01931-0</pub-id><pub-id pub-id-type="pmid">32951604</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Dissing-Olesen</surname><given-names>L</given-names></name><name><surname>Stevens</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>New insights on the role of microglia in synaptic pruning in health and disease</article-title><source>Current Opinion in Neurobiology</source><volume>36</volume><fpage>128</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2015.12.004</pub-id><pub-id pub-id-type="pmid">26745839</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Hitchcock</surname><given-names>PF</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The role of microglia in the neurogenesis of zebrafish retina</article-title><source>Biochemical and Biophysical Research Communications</source><volume>421</volume><fpage>214</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.03.139</pub-id><pub-id pub-id-type="pmid">22497888</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>TF</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Liang</surname><given-names>YX</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>So</surname><given-names>KF</given-names></name><name><surname>Rao</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dual extra-retinal origins of microglia in the model of retinal microglia repopulation</article-title><source>Cell Discovery</source><volume>4</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1038/s41421-018-0011-8</pub-id><pub-id pub-id-type="pmid">29507754</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>KR</given-names></name><name><surname>Cowley</surname><given-names>S</given-names></name><name><surname>Martinez</surname><given-names>FO</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Minger</surname><given-names>SL</given-names></name><name><surname>James</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3</article-title><source>Experimental Hematology</source><volume>36</volume><fpage>1167</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2008.04.009</pub-id><pub-id pub-id-type="pmid">18550257</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlstetter</surname><given-names>M</given-names></name><name><surname>Scholz</surname><given-names>R</given-names></name><name><surname>Rutar</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name><name><surname>Provis</surname><given-names>JM</given-names></name><name><surname>Langmann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Retinal microglia: just bystander or target for therapy?</article-title><source>Progress in Retinal and Eye Research</source><volume>45</volume><fpage>30</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2014.11.004</pub-id><pub-id pub-id-type="pmid">25476242</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubota</surname><given-names>Y</given-names></name><name><surname>Takubo</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Ohno</surname><given-names>H</given-names></name><name><surname>Kishi</surname><given-names>K</given-names></name><name><surname>Shibuya</surname><given-names>M</given-names></name><name><surname>Saya</surname><given-names>H</given-names></name><name><surname>Suda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis</article-title><source>The Journal of Experimental Medicine</source><volume>206</volume><fpage>1089</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1084/jem.20081605</pub-id><pub-id pub-id-type="pmid">19398755</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larochelle</surname><given-names>A</given-names></name><name><surname>Bellavance</surname><given-names>MA</given-names></name><name><surname>Michaud</surname><given-names>JP</given-names></name><name><surname>Rivest</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bone marrow-derived macrophages and the CNS: An update on the use of experimental chimeric mouse models and bone marrow transplantation in neurological disorders</article-title><source>Biochimica et Biophysica Acta</source><volume>1862</volume><fpage>310</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2015.09.017</pub-id><pub-id pub-id-type="pmid">26432480</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>LL</given-names></name><name><surname>Croze</surname><given-names>RH</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Nadar</surname><given-names>VP</given-names></name><name><surname>Clevenger</surname><given-names>TN</given-names></name><name><surname>Pennington</surname><given-names>BO</given-names></name><name><surname>Gamm</surname><given-names>DM</given-names></name><name><surname>Clegg</surname><given-names>DO</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Induced pluripotent stem cell-derived retinal pigmented epithelium: A comparative study between cell lines and differentiation methods</article-title><source>Journal of Ocular Pharmacology and Therapeutics</source><volume>32</volume><fpage>317</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1089/jop.2016.0022</pub-id><pub-id pub-id-type="pmid">27182743</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Liang</surname><given-names>KJ</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Ex vivo dynamic imaging of retinal microglia using time-lapse confocal microscopy</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>49</volume><fpage>4169</fpage><lpage>4176</lpage><pub-id pub-id-type="doi">10.1167/iovs.08-2076</pub-id><pub-id pub-id-type="pmid">18487378</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Microglia and macrophages in brain homeostasis and disease</article-title><source>Nature Reviews. Immunology</source><volume>18</volume><fpage>225</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.125</pub-id><pub-id pub-id-type="pmid">29151590</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>H</given-names></name><name><surname>Pieber</surname><given-names>M</given-names></name><name><surname>Parsa</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Grommisch</surname><given-names>D</given-names></name><name><surname>Ewing</surname><given-names>E</given-names></name><name><surname>Kular</surname><given-names>L</given-names></name><name><surname>Needhamsen</surname><given-names>M</given-names></name><name><surname>Espinosa</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>E</given-names></name><name><surname>Överby</surname><given-names>AK</given-names></name><name><surname>Butovsky</surname><given-names>O</given-names></name><name><surname>Jagodic</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>XM</given-names></name><name><surname>Harris</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Competitive repopulation of an empty microglial niche yields functionally distinct subsets of microglia-like cells</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4845</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-07295-7</pub-id><pub-id pub-id-type="pmid">30451869</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Cerbini</surname><given-names>T</given-names></name><name><surname>San</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Rao</surname><given-names>MS</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Stable enhanced green fluorescent protein expression after differentiation and transplantation of reporter human induced pluripotent stem cells generated by AAVS1 transcription activator-like effector nucleases</article-title><source>Stem Cells Translational Medicine</source><volume>3</volume><fpage>821</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.5966/sctm.2013-0212</pub-id><pub-id pub-id-type="pmid">24833591</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Fontainhas</surname><given-names>AM</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Microglia in the mouse retina alter the structure and function of retinal pigmented epithelial cells: a potential cellular interaction relevant to AMD</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e7945</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0007945</pub-id><pub-id pub-id-type="pmid">19936204</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Microglia in the outer retina and their relevance to pathogenesis of age-related macular degeneration</article-title><source>Advances in Experimental Medicine and Biology</source><volume>723</volume><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1007/978-1-4614-0631-0_6</pub-id><pub-id pub-id-type="pmid">22183313</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Cojocaru</surname><given-names>R</given-names></name><name><surname>Gotoh</surname><given-names>N</given-names></name><name><surname>Gieser</surname><given-names>L</given-names></name><name><surname>Villasmil</surname><given-names>R</given-names></name><name><surname>Cogliati</surname><given-names>T</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Gene expression changes in aging retinal microglia: relationship to microglial support functions and regulation of activation</article-title><source>Neurobiology of Aging</source><volume>34</volume><fpage>2310</fpage><lpage>2321</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.03.022</pub-id><pub-id pub-id-type="pmid">23608111</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Tam</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Monocyte infiltration and proliferation reestablish myeloid cell homeostasis in the mouse retina following retinal pigment epithelial cell injury</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>8433</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-08702-7</pub-id><pub-id pub-id-type="pmid">28814744</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>R</given-names></name><name><surname>Van Den Daele</surname><given-names>J</given-names></name><name><surname>Fattorelli</surname><given-names>N</given-names></name><name><surname>Wolfs</surname><given-names>L</given-names></name><name><surname>Balusu</surname><given-names>S</given-names></name><name><surname>Burton</surname><given-names>O</given-names></name><name><surname>Liston</surname><given-names>A</given-names></name><name><surname>Sierksma</surname><given-names>A</given-names></name><name><surname>Fourne</surname><given-names>Y</given-names></name><name><surname>Poovathingal</surname><given-names>S</given-names></name><name><surname>Arranz-Mendiguren</surname><given-names>A</given-names></name><name><surname>Sala Frigerio</surname><given-names>C</given-names></name><name><surname>Claes</surname><given-names>C</given-names></name><name><surname>Serneels</surname><given-names>L</given-names></name><name><surname>Theys</surname><given-names>T</given-names></name><name><surname>Perry</surname><given-names>VH</given-names></name><name><surname>Verfaillie</surname><given-names>C</given-names></name><name><surname>Fiers</surname><given-names>M</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Stem-cell-derived human microglia transplanted in mouse brain to study human disease</article-title><source>Nature Neuroscience</source><volume>22</volume><fpage>2111</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0525-x</pub-id><pub-id pub-id-type="pmid">31659342</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muffat</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>B</given-names></name><name><surname>Mitalipova</surname><given-names>M</given-names></name><name><surname>Omer</surname><given-names>A</given-names></name><name><surname>Corcoran</surname><given-names>S</given-names></name><name><surname>Bakiasi</surname><given-names>G</given-names></name><name><surname>Tsai</surname><given-names>LH</given-names></name><name><surname>Aubourg</surname><given-names>P</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Efficient derivation of microglia-like cells from human pluripotent stem cells</article-title><source>Nature Medicine</source><volume>22</volume><fpage>1358</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1038/nm.4189</pub-id><pub-id pub-id-type="pmid">27668937</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nau</surname><given-names>R</given-names></name><name><surname>Ribes</surname><given-names>S</given-names></name><name><surname>Djukic</surname><given-names>M</given-names></name><name><surname>Eiffert</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Strategies to increase the activity of microglia as efficient protectors of the brain against infections</article-title><source>Frontiers in Cellular Neuroscience</source><volume>8</volume><elocation-id>138</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2014.00138</pub-id><pub-id pub-id-type="pmid">24904283</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Microglia: a cellular vehicle for CNS gene therapy</article-title><source>The Journal of Clinical Investigation</source><volume>116</volume><fpage>2857</fpage><lpage>2860</lpage><pub-id pub-id-type="doi">10.1172/JCI30230</pub-id><pub-id pub-id-type="pmid">17080190</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okunuki</surname><given-names>Y</given-names></name><name><surname>Mukai</surname><given-names>R</given-names></name><name><surname>Nakao</surname><given-names>T</given-names></name><name><surname>Tabor</surname><given-names>SJ</given-names></name><name><surname>Butovsky</surname><given-names>O</given-names></name><name><surname>Dana</surname><given-names>R</given-names></name><name><surname>Ksander</surname><given-names>BR</given-names></name><name><surname>Connor</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Retinal microglia initiate neuroinflammation in ocular autoimmunity</article-title><source>PNAS</source><volume>116</volume><fpage>9989</fpage><lpage>9998</lpage><pub-id pub-id-type="doi">10.1073/pnas.1820387116</pub-id><pub-id pub-id-type="pmid">31023885</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandya</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>MJ</given-names></name><name><surname>Ichikawa</surname><given-names>DM</given-names></name><name><surname>Sedlock</surname><given-names>AB</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Johnson</surname><given-names>KR</given-names></name><name><surname>Kim</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Elkahloun</surname><given-names>AG</given-names></name><name><surname>Maric</surname><given-names>D</given-names></name><name><surname>Sweeney</surname><given-names>CL</given-names></name><name><surname>Gossa</surname><given-names>S</given-names></name><name><surname>Malech</surname><given-names>HL</given-names></name><name><surname>McGavern</surname><given-names>DB</given-names></name><name><surname>Park</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Differentiation of human and murine induced pluripotent stem cells to microglia-like cells</article-title><source>Nature Neuroscience</source><volume>20</volume><fpage>753</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1038/nn.4534</pub-id><pub-id pub-id-type="pmid">28253233</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paolicelli</surname><given-names>RC</given-names></name><name><surname>Bolasco</surname><given-names>G</given-names></name><name><surname>Pagani</surname><given-names>F</given-names></name><name><surname>Maggi</surname><given-names>L</given-names></name><name><surname>Scianni</surname><given-names>M</given-names></name><name><surname>Panzanelli</surname><given-names>P</given-names></name><name><surname>Giustetto</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>TA</given-names></name><name><surname>Guiducci</surname><given-names>E</given-names></name><name><surname>Dumas</surname><given-names>L</given-names></name><name><surname>Ragozzino</surname><given-names>D</given-names></name><name><surname>Gross</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Synaptic pruning by microglia is necessary for normal brain development</article-title><source>Science</source><volume>333</volume><fpage>1456</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1126/science.1202529</pub-id><pub-id pub-id-type="pmid">21778362</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parajuli</surname><given-names>B</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Shinozaki</surname><given-names>Y</given-names></name><name><surname>Shigetomi</surname><given-names>E</given-names></name><name><surname>Miwa</surname><given-names>H</given-names></name><name><surname>Yoneda</surname><given-names>S</given-names></name><name><surname>Tanimura</surname><given-names>M</given-names></name><name><surname>Omachi</surname><given-names>S</given-names></name><name><surname>Asaki</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Nakashima</surname><given-names>K</given-names></name><name><surname>Koizumi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transnasal transplantation of human induced pluripotent stem cell-derived microglia to the brain of immunocompetent mice</article-title><source>Glia</source><volume>69</volume><fpage>2332</fpage><lpage>2348</lpage><pub-id pub-id-type="doi">10.1002/glia.23985</pub-id><pub-id pub-id-type="pmid">34309082</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>K</given-names></name><name><surname>Beers</surname><given-names>J</given-names></name><name><surname>Linask</surname><given-names>KL</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Hassanzadeh</surname><given-names>S</given-names></name><name><surname>Sack</surname><given-names>MN</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Generation of two induced pluripotent stem cell lines (NHLBIi001-A and NHLBIi001-B) from A healthy Caucasian female volunteer with normal cardiac function</article-title><source>Stem Cell Research</source><volume>41</volume><elocation-id>101627</elocation-id><pub-id pub-id-type="doi">10.1016/j.scr.2019.101627</pub-id><pub-id pub-id-type="pmid">31733441</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>K</given-names></name><name><surname>Linask</surname><given-names>KL</given-names></name><name><surname>Beers</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Generation of two tdTomato reporter induced pluripotent stem cell lines (NHLBIi003-A-1 and NHLBIi003-A-2) by AAVS1 safe harbor gene-editing</article-title><source>Stem Cell Research</source><volume>42</volume><elocation-id>101673</elocation-id><pub-id pub-id-type="doi">10.1016/j.scr.2019.101673</pub-id><pub-id pub-id-type="pmid">31869686</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pocock</surname><given-names>JM</given-names></name><name><surname>Piers</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Modelling microglial function with induced pluripotent stem cells: an update</article-title><source>Nature Reviews. Neuroscience</source><volume>19</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/s41583-018-0030-3</pub-id><pub-id pub-id-type="pmid">29977068</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puñal</surname><given-names>VM</given-names></name><name><surname>Paisley</surname><given-names>CE</given-names></name><name><surname>Brecha</surname><given-names>FS</given-names></name><name><surname>Lee</surname><given-names>MA</given-names></name><name><surname>Perelli</surname><given-names>RM</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>O’Koren</surname><given-names>EG</given-names></name><name><surname>Ackley</surname><given-names>CR</given-names></name><name><surname>Saban</surname><given-names>DR</given-names></name><name><surname>Reese</surname><given-names>BE</given-names></name><name><surname>Kay</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Large-scale death of retinal astrocytes during normal development is non-apoptotic and implemented by microglia</article-title><source>PLOS Biology</source><volume>17</volume><elocation-id>e3000492</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000492</pub-id><pub-id pub-id-type="pmid">31626642</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramírez</surname><given-names>AI</given-names></name><name><surname>de Hoz</surname><given-names>R</given-names></name><name><surname>Fernández-Albarral</surname><given-names>JA</given-names></name><name><surname>Salobrar-Garcia</surname><given-names>E</given-names></name><name><surname>Rojas</surname><given-names>B</given-names></name><name><surname>Valiente-Soriano</surname><given-names>FJ</given-names></name><name><surname>Avilés-Trigueros</surname><given-names>M</given-names></name><name><surname>Villegas-Pérez</surname><given-names>MP</given-names></name><name><surname>Vidal-Sanz</surname><given-names>M</given-names></name><name><surname>Triviño</surname><given-names>A</given-names></name><name><surname>Ramírez</surname><given-names>JM</given-names></name><name><surname>Salazar</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Time course of bilateral microglial activation in a mouse model of laser-induced glaucoma</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>4890</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-61848-9</pub-id><pub-id pub-id-type="pmid">32184450</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Réu</surname><given-names>P</given-names></name><name><surname>Khosravi</surname><given-names>A</given-names></name><name><surname>Bernard</surname><given-names>S</given-names></name><name><surname>Mold</surname><given-names>JE</given-names></name><name><surname>Salehpour</surname><given-names>M</given-names></name><name><surname>Alkass</surname><given-names>K</given-names></name><name><surname>Perl</surname><given-names>S</given-names></name><name><surname>Tisdale</surname><given-names>J</given-names></name><name><surname>Possnert</surname><given-names>G</given-names></name><name><surname>Druid</surname><given-names>H</given-names></name><name><surname>Frisén</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The lifespan and turnover of microglia in the human brain</article-title><source>Cell Reports</source><volume>20</volume><fpage>779</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.07.004</pub-id><pub-id pub-id-type="pmid">28746864</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritter</surname><given-names>MR</given-names></name><name><surname>Banin</surname><given-names>E</given-names></name><name><surname>Moreno</surname><given-names>SK</given-names></name><name><surname>Aguilar</surname><given-names>E</given-names></name><name><surname>Dorrell</surname><given-names>MI</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy</article-title><source>The Journal of Clinical Investigation</source><volume>116</volume><fpage>3266</fpage><lpage>3276</lpage><pub-id pub-id-type="doi">10.1172/JCI29683</pub-id><pub-id pub-id-type="pmid">17111048</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>DP</given-names></name><name><surname>Lehrman</surname><given-names>EK</given-names></name><name><surname>Kautzman</surname><given-names>AG</given-names></name><name><surname>Koyama</surname><given-names>R</given-names></name><name><surname>Mardinly</surname><given-names>AR</given-names></name><name><surname>Yamasaki</surname><given-names>R</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name><name><surname>Stevens</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner</article-title><source>Neuron</source><volume>74</volume><fpage>691</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.03.026</pub-id><pub-id pub-id-type="pmid">22632727</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>DP</given-names></name><name><surname>Stevens</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Microglia function in central nervous system development and plasticity</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>7</volume><elocation-id>a020545</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a020545</pub-id><pub-id pub-id-type="pmid">26187728</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Saliba</surname><given-names>A</given-names></name><name><surname>Bhat</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Microglial mTOR Activation Upregulates Trem2 and Enhances β-Amyloid Plaque Clearance in the <italic>5XFAD</italic> Alzheimer’s Disease Model</article-title><source>The Journal of Neuroscience</source><volume>42</volume><fpage>5294</fpage><lpage>5313</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2427-21.2022</pub-id><pub-id pub-id-type="pmid">35672148</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibuya</surname><given-names>Y</given-names></name><name><surname>Kumar</surname><given-names>KK</given-names></name><name><surname>Mader</surname><given-names>MM-D</given-names></name><name><surname>Yoo</surname><given-names>Y</given-names></name><name><surname>Ayala</surname><given-names>LA</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Mohr</surname><given-names>MA</given-names></name><name><surname>Neumayer</surname><given-names>G</given-names></name><name><surname>Kumar</surname><given-names>I</given-names></name><name><surname>Yamamoto</surname><given-names>R</given-names></name><name><surname>Marcoux</surname><given-names>P</given-names></name><name><surname>Liou</surname><given-names>B</given-names></name><name><surname>Bennett</surname><given-names>FC</given-names></name><name><surname>Nakauchi</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Heppner</surname><given-names>FL</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Treatment of a genetic brain disease by CNS-wide microglia replacement</article-title><source>Science Translational Medicine</source><volume>14</volume><elocation-id>eabl9945</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abl9945</pub-id><pub-id pub-id-type="pmid">35294256</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>A</given-names></name><name><surname>Abiega</surname><given-names>O</given-names></name><name><surname>Shahraz</surname><given-names>A</given-names></name><name><surname>Neumann</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis</article-title><source>Frontiers in Cellular Neuroscience</source><volume>7</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2013.00006</pub-id><pub-id pub-id-type="pmid">23386811</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>SM</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>C3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa</article-title><source>The Journal of Experimental Medicine</source><volume>216</volume><fpage>1925</fpage><lpage>1943</lpage><pub-id pub-id-type="doi">10.1084/jem.20190009</pub-id><pub-id pub-id-type="pmid">31209071</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Dragunow</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The human side of microglia</article-title><source>Trends in Neurosciences</source><volume>37</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2013.12.001</pub-id><pub-id pub-id-type="pmid">24388427</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>B</given-names></name><name><surname>Allen</surname><given-names>NJ</given-names></name><name><surname>Vazquez</surname><given-names>LE</given-names></name><name><surname>Howell</surname><given-names>GR</given-names></name><name><surname>Christopherson</surname><given-names>KS</given-names></name><name><surname>Nouri</surname><given-names>N</given-names></name><name><surname>Micheva</surname><given-names>KD</given-names></name><name><surname>Mehalow</surname><given-names>AK</given-names></name><name><surname>Huberman</surname><given-names>AD</given-names></name><name><surname>Stafford</surname><given-names>B</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><name><surname>Litke</surname><given-names>AM</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Smith</surname><given-names>SJ</given-names></name><name><surname>John</surname><given-names>SWM</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The classical complement cascade mediates CNS synapse elimination</article-title><source>Cell</source><volume>131</volume><fpage>1164</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.10.036</pub-id><pub-id pub-id-type="pmid">18083105</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svoboda</surname><given-names>DS</given-names></name><name><surname>Barrasa</surname><given-names>MI</given-names></name><name><surname>Shu</surname><given-names>J</given-names></name><name><surname>Rietjens</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Mitalipova</surname><given-names>M</given-names></name><name><surname>Berube</surname><given-names>P</given-names></name><name><surname>Fu</surname><given-names>D</given-names></name><name><surname>Shultz</surname><given-names>LD</given-names></name><name><surname>Bell</surname><given-names>GW</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human iPSC-derived microglia assume a primary microglia-like state after transplantation into the neonatal mouse brain</article-title><source>PNAS</source><volume>116</volume><fpage>25293</fpage><lpage>25303</lpage><pub-id pub-id-type="doi">10.1073/pnas.1913541116</pub-id><pub-id pub-id-type="pmid">31772018</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takata</surname><given-names>K</given-names></name><name><surname>Kozaki</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>CZW</given-names></name><name><surname>Thion</surname><given-names>MS</given-names></name><name><surname>Otsuka</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Utami</surname><given-names>KH</given-names></name><name><surname>Fidan</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>DS</given-names></name><name><surname>Malleret</surname><given-names>B</given-names></name><name><surname>Chakarov</surname><given-names>S</given-names></name><name><surname>See</surname><given-names>P</given-names></name><name><surname>Low</surname><given-names>D</given-names></name><name><surname>Low</surname><given-names>G</given-names></name><name><surname>Garcia-Miralles</surname><given-names>M</given-names></name><name><surname>Zeng</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Goh</surname><given-names>CC</given-names></name><name><surname>Gul</surname><given-names>A</given-names></name><name><surname>Hubert</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Low</surname><given-names>I</given-names></name><name><surname>Shadan</surname><given-names>NB</given-names></name><name><surname>Lum</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>TS</given-names></name><name><surname>Mok</surname><given-names>E</given-names></name><name><surname>Kawanishi</surname><given-names>S</given-names></name><name><surname>Kitamura</surname><given-names>Y</given-names></name><name><surname>Larbi</surname><given-names>A</given-names></name><name><surname>Poidinger</surname><given-names>M</given-names></name><name><surname>Renia</surname><given-names>L</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name><name><surname>Wolf</surname><given-names>Y</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Önder</surname><given-names>T</given-names></name><name><surname>Newell</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>T</given-names></name><name><surname>Ashihara</surname><given-names>E</given-names></name><name><surname>Garel</surname><given-names>S</given-names></name><name><surname>Pouladi</surname><given-names>MA</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Induced-pluripotent-stem-cell-derived primitive macrophages provide a platform for modeling tissue-resident macrophage differentiation and function</article-title><source>Immunity</source><volume>47</volume><fpage>183</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.06.017</pub-id><pub-id pub-id-type="pmid">28723550</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name><name><surname>Tamalu</surname><given-names>F</given-names></name><name><surname>Watanabe</surname><given-names>S-I</given-names></name><name><surname>Nishina</surname><given-names>S</given-names></name><name><surname>Azuma</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Generation of retinal ganglion cells with functional axons from mouse embryonic stem cells and induced pluripotent stem cells</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>57</volume><fpage>3348</fpage><lpage>3359</lpage><pub-id pub-id-type="doi">10.1167/iovs.16-19166</pub-id><pub-id pub-id-type="pmid">27367502</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Gullipalli</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Modeling complement-driven diseases in transgenic mice: Values and limitations</article-title><source>Immunobiology</source><volume>221</volume><fpage>1080</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2016.06.007</pub-id><pub-id pub-id-type="pmid">27371974</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulland</surname><given-names>TK</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TREM2 - a key player in microglial biology and Alzheimer disease</article-title><source>Nature Reviews. Neurology</source><volume>14</volume><fpage>667</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/s41582-018-0072-1</pub-id><pub-id pub-id-type="pmid">30266932</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Poel</surname><given-names>M</given-names></name><name><surname>Ulas</surname><given-names>T</given-names></name><name><surname>Mizee</surname><given-names>MR</given-names></name><name><surname>Hsiao</surname><given-names>CC</given-names></name><name><surname>Miedema</surname><given-names>SSM</given-names></name><name><surname>Schuurman</surname><given-names>KG</given-names></name><name><surname>Helder</surname><given-names>B</given-names></name><name><surname>Tas</surname><given-names>SW</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Hamann</surname><given-names>J</given-names></name><name><surname>Huitinga</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcriptional profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-associated changes</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1139</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08976-7</pub-id><pub-id pub-id-type="pmid">30867424</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Wilgenburg</surname><given-names>B</given-names></name><name><surname>Browne</surname><given-names>C</given-names></name><name><surname>Vowles</surname><given-names>J</given-names></name><name><surname>Cowley</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e71098</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0071098</pub-id><pub-id pub-id-type="pmid">23951090</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Rodriguez</surname><given-names>IR</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Macroglia-microglia interactions via TSPO signaling regulates microglial activation in the mouse retina</article-title><source>The Journal of Neuroscience</source><volume>34</volume><fpage>3793</fpage><lpage>3806</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3153-13.2014</pub-id><pub-id pub-id-type="pmid">24599476</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Kretschmer</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Qian</surname><given-names>HH</given-names></name><name><surname>Badea</surname><given-names>TC</given-names></name><name><surname>Diamond</surname><given-names>JS</given-names></name><name><surname>Gan</surname><given-names>W-B</given-names></name><name><surname>Roger</surname><given-names>JE</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Requirement for microglia for the maintenance of synaptic function and integrity in the mature retina</article-title><source>The Journal of Neuroscience</source><volume>36</volume><fpage>2827</fpage><lpage>2842</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3575-15.2016</pub-id><pub-id pub-id-type="pmid">26937019</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Mustafa</surname><given-names>M</given-names></name><name><surname>Yuede</surname><given-names>CM</given-names></name><name><surname>Salazar</surname><given-names>SV</given-names></name><name><surname>Kong</surname><given-names>P</given-names></name><name><surname>Long</surname><given-names>H</given-names></name><name><surname>Ward</surname><given-names>M</given-names></name><name><surname>Siddiqui</surname><given-names>O</given-names></name><name><surname>Paul</surname><given-names>R</given-names></name><name><surname>Gilfillan</surname><given-names>S</given-names></name><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Rhinn</surname><given-names>H</given-names></name><name><surname>Tassi</surname><given-names>I</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Schwabe</surname><given-names>T</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model</article-title><source>The Journal of Experimental Medicine</source><volume>217</volume><elocation-id>e20200785</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20200785</pub-id><pub-id pub-id-type="pmid">32579671</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>EF</given-names></name><name><surname>MacDonald</surname><given-names>KPA</given-names></name><name><surname>Nguyen</surname><given-names>QH</given-names></name><name><surname>Garrido</surname><given-names>AL</given-names></name><name><surname>Gillespie</surname><given-names>ER</given-names></name><name><surname>Harley</surname><given-names>SBR</given-names></name><name><surname>Bartlett</surname><given-names>PF</given-names></name><name><surname>Schroder</surname><given-names>WA</given-names></name><name><surname>Yates</surname><given-names>AG</given-names></name><name><surname>Anthony</surname><given-names>DC</given-names></name><name><surname>Rose-John</surname><given-names>S</given-names></name><name><surname>Ruitenberg</surname><given-names>MJ</given-names></name><name><surname>Vukovic</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Repopulating Microglia Promote Brain Repair in an IL-6-Dependent Manner</article-title><source>Cell</source><volume>180</volume><fpage>833</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.013</pub-id><pub-id pub-id-type="pmid">32142677</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Diabetic retinopathy and dysregulated innate immunity</article-title><source>Vision Research</source><volume>139</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.visres.2017.04.013</pub-id><pub-id pub-id-type="pmid">28571700</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Boreland</surname><given-names>AJ</given-names></name><name><surname>Posyton</surname><given-names>A</given-names></name><name><surname>Kwan</surname><given-names>K</given-names></name><name><surname>Hart</surname><given-names>RP</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Human iPSC-derived mature microglia retain their identity and functionally integrate in the chimeric mouse brain</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1577</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15411-9</pub-id><pub-id pub-id-type="pmid">32221280</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Rao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Feng</surname><given-names>R</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>TF</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>B</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Efficient strategies for microglia replacement in the central nervous system</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108443</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108443</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Lazere</surname><given-names>A</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Abu-Asab</surname><given-names>M</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Roger</surname><given-names>JE</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Repopulating retinal microglia restore endogenous organization and function under CX3CL1-CX3CR1 regulation</article-title><source>Science Advances</source><volume>4</volume><elocation-id>eaap8492</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aap8492</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Minocycline attenuates photoreceptor degeneration in a mouse model of subretinal hemorrhage microglial: inhibition as a potential therapeutic strategy</article-title><source>The American Journal of Pathology</source><volume>179</volume><fpage>1265</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.05.042</pub-id><pub-id pub-id-type="pmid">21763674</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Zabel</surname><given-names>MK</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Parkhurst</surname><given-names>CN</given-names></name><name><surname>Gan</surname><given-names>WB</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration</article-title><source>EMBO Molecular Medicine</source><volume>7</volume><fpage>1179</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.15252/emmm.201505298</pub-id><pub-id pub-id-type="pmid">26139610</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Gutierrez</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>T</given-names></name><name><surname>Hampton</surname><given-names>C</given-names></name><name><surname>Vergara</surname><given-names>MN</given-names></name><name><surname>Cao</surname><given-names>LH</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>TS</given-names></name><name><surname>Zambidis</surname><given-names>ET</given-names></name><name><surname>Meyer</surname><given-names>JS</given-names></name><name><surname>Gamm</surname><given-names>DM</given-names></name><name><surname>Yau</surname><given-names>KW</given-names></name><name><surname>Canto-Soler</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>4047</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms5047</pub-id><pub-id pub-id-type="pmid">24915161</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>A</given-names></name><name><surname>Vakal</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A combination of inhibiting microglia activity and remodeling gut microenvironment suppresses the development and progression of experimental autoimmune uveitis</article-title><source>Biochemical Pharmacology</source><volume>180</volume><elocation-id>114108</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2020.114108</pub-id><pub-id pub-id-type="pmid">32569628</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90695.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiaorong</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Virginia</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>The authors have improved a method to differentiate human iPSC-derived microglial cells with immune responses and phagocytic abilities; and through transplantation into the adult mouse retina, the authors further demonstrated their integration and occupation of native microglial cell space, and functional response to retinal injuries. The study is <bold>important</bold> and the data are <bold>convincing</bold> for potential microglial replacement therapy to treat retinal and CNS diseases.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90695.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This paper reported a protocol of using human-induced pluripotent stem cells to generate cells expressing microglia-enriched genes and responding to LPS by drastically upregulation of proinflammatory cytokines. Upon subretinal transplantation in mice, hiPSC-derived cells integrated into the host retina and maintained retinal homeostasis while they responded to RPE injury by migration, proliferation, and phagocytosis. The findings revealed the potential of using hiPSC-derived cell transplantation for microglia replacement as a therapeutic strategy for retinal diseases.</p><p>Strengths:</p><p>The paper demonstrates a method of consistently generating a significant quantity of hiPSC-derived microglia-like cells for in vitro study or for in vivo transplantation. RNAseq analysis offers an opportunity for comprehensive transcriptome profiling of the derived cells. It is impressive that following transplantation, these cells were well integrated into the retina, migrated to the corresponding layers, adopted microglia-like morphologies, and survived for a long term without generating apparent harm. The work has laid a foundation for future utilization of hiPSC-derived microglia in lab and clinical applications.</p><p>Weaknesses:</p><p>(1) The primary weakness of the paper concerns its conclusion of having generated &quot;homogenous mature microglia&quot;, partly based on the RNAseq analysis. However, the comparison of gene profiles was carried out only between &quot;hiPSC-derived mature microglia&quot; and the proliferating myeloid progenitors. While the transcriptome profiles revealed a trend of enrichment of microglia-like gene expression in &quot;hiPSC-derived mature microglia&quot; compared to proliferating myeloid progenitors, this is not sufficient to claim they are &quot;mature microglia&quot;. It is important that one carries out a comparative analysis of the RNAseq data with those of primary human microglia, which may be done by leveraging the public database. To convincingly claim these cells are mature microglia, questions to be addressed include how similar the molecular signatures of these cells are compared with the fully differentiated primary microglia cell or if they remain progenitor-like or take on mosaic properties, and how they distinguish from macrophages.</p><p>(2) While the authors attempted to demonstrate the functional property of &quot;hiPSC-derived mature microglia&quot; in culture, they used LPS challenge, which is an inappropriate assay. This is because human microglia respond poorly to LPS alone but need to be activated by a combination of LPS with other factors, such as IFNγ. Their data that &quot;hiPSC-derived mature microglia&quot; showed robust responses to LPS indeed implicates that these cells do not behave like mature human microglia.</p><p>(3) The resolution of Figs. 4 - 6 is so low that even some of the text and labels are hardly readable. Based on the morphology shown in Fig. 4 and the statement in line 147, these hiPSC-derived &quot;cells altered their morphology to a rounded shape within an hour of incubation and rapidly internalized the fluorescent-labeled particles&quot;. This is a peculiar response. Usually, microglia do not respond to fluorescent-labeled zymosan by turning into a rounded-shaped morphology within an hour when they internalize them. Such a behavior usually implicates weak phagocytotic capacity.</p><p>(4) Data presented in Fig. 5 are not very convincing to support that transplanted cells were immunopositive for &quot;human CD11b (Fig.5C), as well as microglia signature markers P2ry12 and TMEM119 (Fig.5D)&quot; (line 167). The resolution and magnification of Fig. 5D are too low to tell the colocalization of tdT and human microglial marker immunolabeling. In the flat-mount images (C, I), hCD11b immunolabeling is not visible in the GCL or barely visible in the IPL. This should be discussed.</p><p>(5) Microglia respond to injury by becoming active and losing their expression of the resting state microglial marker, such as P2ry12, which is used in Fig. 6 for the detection of migrated microglia. To confirm that these cells indeed respond to injury like native microglia, one should check for activated microglial markers and induction of pro-inflammatory cytokines in the sodium iodate-injury model.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90695.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Ma et al. employed a myeloid progenitor/microglia differentiation protocol to produce human-induced pluripotent stem cell (hiPSC)-derived microglia in order to examine the potential of microglial cell replacement as a treatment for retinal disorders. They characterized the iPSC-derived microglia by gene expression and in vitro assay analysis. By evaluating xenografted microglia in the partly microglia-depleted retina, the function of the microglia was further assessed.</p><p>Overall, the study and the data are convincing, and xenografted microglia were also tested in a RPE injury paradigm.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90695.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Wenxin</given-names></name><role specific-use="author">Author</role><aff><institution>National Eye Institute</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Lian</given-names></name><role specific-use="author">Author</role><aff><institution>National Eye Institute, NIH</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Biying</given-names></name><role specific-use="author">Author</role><aff><institution>National Eye Institute</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Fariss</surname><given-names>Robert N</given-names></name><role specific-use="author">Author</role><aff><institution>National Eye Institute</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Redmond</surname><given-names>T Michael</given-names></name><role specific-use="author">Author</role><aff><institution>National Eye Institute, National Institutes of Health</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Jizhong</given-names></name><role specific-use="author">Author</role><aff><institution>NHLBI/NIH</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Wai</given-names></name><role specific-use="author">Author</role><aff><institution>Tiresias Bio</institution><addr-line><named-content content-type="city">Half Moon Bay, CA</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Wei</given-names></name><role specific-use="author">Author</role><aff><institution>National Eye Institute</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>(1) The primary weakness of the paper concerns its conclusion of having generated &quot;homogenous mature microglia&quot;, partly based on the RNAseq analysis. However, the comparison of gene profiles was carried out only between &quot;hiPSC-derived mature microglia&quot; and the proliferating myeloid progenitors. While the transcriptome profiles revealed a trend of enrichment of microglia-like gene expression in &quot;hiPSC-derived mature microglia&quot; compared to proliferating myeloid progenitors, this is not sufficient to claim they are &quot;mature microglia&quot;. It is important that one carries out a comparative analysis of the RNAseq data with those of primary human microglia, which may be done by leveraging the public database. To convincingly claim these cells are mature microglia, questions need to be addressed including how similar the molecular signatures of these cells are compared with the fully differentiated primary microglia cell or if they remain progenitor-like or take on mosaic properties, and how they distinguish from macrophages.</p></disp-quote><p>We greatly appreciate the insightful comments and suggestions from the reviewers, which were instrumental in enhancing our data analysis and organization. In response to the feedback, we have updated the terminology from “mature microglia” to simply “microglia” while clarifying in our text that these are fully differentiated microglia under single-type cell culture conditions.</p><p>Guided by the reviewer's advice, we incorporated RNA-seq data from human brain microglia studies conducted by Dr. Poon and Dr. Blurton-Jones' Lab (Abud et al., Neuron, 2017) and Dr. Huitinga's Lab (van der Poel et al., Nat Commun, 2019). We then conducted a comparative analysis of the gene expression profiles between our fully differentiated hiPSC-derived microglia and those from fetal/adult brain microglia (see Fig.2. Suppl. B, C and D; Suppl. table 1 and table 2). The correlation analysis revealed that our hiPSC-derived microglia closely resemble fetal and adult brain microglia, distinguishing them significantly from monocytes and inflammatory monocytes.</p><disp-quote content-type="editor-comment"><p>(2) While the authors attempted to demonstrate the functional property of &quot;hiPSC-derived mature microglia&quot; in culture, they used LPS challenge, which is an inappropriate assay. This is because human microglia respond poorly to LPS alone but need to be activated by a combination of LPS with other factors, such as IFNγ. Their data that &quot;hiPSC-derived mature microglia&quot; showed robust responses to LPS indeed implicates that these cells do not behave like mature human microglia.</p></disp-quote><p>We appreciate the feedback received. In response, we cultured hiPSC-derived microglia cells and subjected them to treatments with IFNγ, LPS, and a combination of both IFNγ+LPS, as illustrated in Figure 3 suppl. Our findings revealed that the IFNγ+LPS combination notably enhanced the expression of IL1a, IL1b, TNFa, CCL8, and CXCL10, whereas IL6 and CCL2 levels remained unchanged. Treatment with IFNγ alone significantly elevated the expression of TNFa, CCL8, CXCL10, and CCL2. These outcomes align with the findings reported by Rustenhoven et al. (Sci Rep, 2016), suggesting that the functionality of our hiPSC-derived microglia cells closely mirrors that of primary human adult microglia cells.</p><disp-quote content-type="editor-comment"><p>(3) The resolution of Figs. 4 - 6 is so low that even some of the text and labels are hardly readable. Based on the morphology shown in Fig. 4 and the statement in line 147, these hiPSC-derived &quot;cells altered their morphology to a rounded shape within an hour of incubation and rapidly internalized the fluorescent-labeled particles&quot;. This is a peculiar response. Usually, microglia do not respond to fluorescent-labeled zymosan by turning into a rounded shaped within an hour when they internalize them. Such a behavior usually implicates weak phagocytotic capacity.</p></disp-quote><p>Thank you for your insightful comments. During submission, the main text's PDF version was converted online, resulting in low-quality output. We have since updated this with a high-resolution version. The observed alterations in cell morphology following zymosan phagocytosis may be attributed to the high zymosan concentration used (2mg/ml). We conducted an assessment to understand the impact of zymosan concentration on the morphology of hiPSC-derived microglial cells, as shown in Figure 4 suppl B. Our findings indicate that microglia cells adopt an amoeboid, rounded shape at zymosan concentrations exceeding 20ug/ml. To clarify this point, we have amended the text to read: &quot;The cells altered their morphology and rapidly internalized the fluorescent-labeled particles.&quot;</p><disp-quote content-type="editor-comment"><p>(4) Data presented in Fig. 5 are not very convincing to support that transplanted cells were immunopositive for &quot;human CD11b (Fig.5C), as well as microglia signature markers P2ry12 and TMEM119 (Fig.5D)&quot; (line 167). The resolution and magnification of Fig. 5D is too low to tell the colocalization of tdT and human microglial marker immunolabeling. In the flat-mount images (C, I), hCD11b immunolabeling is not visible in the GCL or barely visible in the IPL. This should be discussed.</p></disp-quote><p>We are grateful for the reviewer's comments. As previously mentioned, the low quality of the images was due to the online conversion of the PDF version. We have now submitted both high-quality PDF and Word versions for the reviewer's assessment. In these high-quality versions, the colocalization of tdT with human P2ry12 and TMEM119 is distinctly visible. Additionally, we have updated the hTMEM119 staining images in Figure 5D. The results from hCD11b staining align with those observed in mouse CD11b staining, notably showing more effective staining in the outer plexiform layer (OPL) microglia cells. The reason for this—whether it pertains to a staining issue, a variance in CD11b expression among microglia cells in the OPL and ganglion layer (GL), or differences in the samples due to varying conditions—is not yet clear and warrants further investigation.</p><disp-quote content-type="editor-comment"><p>(5) Microglia respond to injury by becoming active and lose their expression of the resting state microglial marker, such as P2ry12, which is used in Fig. 6 for detection of migrated microglia. To confirm that these cells indeed respond to injury like native microglia, one should check for activated microglial markers and induction of pro-inflammatory cytokines in the sodium iodate-injury model.</p></disp-quote><p>The reviewer's insights are spot-on. We utilized preserved retinas to extract mRNA, which was then reverse-transcribed to cDNA for conducting qRT-PCR using human-specific primers, as detailed in the updated Table 5. The findings revealed that following retinal pigment epithelium (RPE) injury for 3 days, the transplanted hiPSC-derived microglial cells exhibited an increase in the production of inflammatory cytokines and upregulated genes related to phagocytosis, migration, and adhesion. Conversely, there was a decrease in the expression of microglia-specific signature genes and neurotrophic factors, as demonstrated in Figure 7 suppl.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>Line 52: &quot;Microglia cell repopulation research suggests that: (1) if no injury or infection occurs, retinal microglia cells can sustain their homeostasis indefinitely&quot; - this statement is too strong or delivers a confusing message; it needs clarification or to be backed up by evidence. Recent single cell RNA sequencing analyses suggest that even under a normal condition, residential microglia do not present as a single homeostatic cell cluster, rather a subpopulation of activated inflammatory microglia are constantly detectable in the normal retina. This is likely because normal retinal neurons can be stressed due to various reasons, such as the temporal accumulation of misfolded proteins, exposed to strong light, or ageing, etc.</p></disp-quote><p>We appreciate the comments. We changed the sentence to read, &quot;Microglia cell repopulation research suggests that: (1) retinal resident microglia cells can sustain their population with the local dividing and migration if any perturbations do not exceed the threshold of the recovery speed by local neighbor microglia cells.&quot;</p><disp-quote content-type="editor-comment"><p>Line 83: &quot;we applied an appropriate protocol for culturing human iPSC-derived microglia cells&quot; - it would be more appropriate if the word &quot;appropriate&quot; can be replaced by either &quot;unique&quot; or a phrase like &quot;we adopted a (previously published) protocol...&quot;.</p></disp-quote><p>Thanks! We changed it to “We modified a previously published protocol to culture human iPSC-derived microglia cells.&quot;.</p><disp-quote content-type="editor-comment"><p>Fig. 1F,G: A method of flow cytometry will provide more comprehensive cell quantification for percentages of positively labeled cells than cell counts under high magnification confocal images.</p></disp-quote><p>Thanks for the comments! We agreed with the reviewer. Given the experimental resources available, the quantifications of confocal images did provide a reasonable assessment. We will perform flow cytometry analysis in future experiments.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Weaknesses:</p><p>Gene expression analysis of mature microglia cells should be better interpreted and it would be beneficial to compare the iPSC-derived microglia gene set to a human microglial cell line (for example, HMC3) instead of myeloid progenitor cells.</p><p>The way that the manuscript has been written, unfortunately, is not optimal. I recommend that the entire manuscript be edited and proofread in English. The text contains spelling and grammar mistakes, and the manuscript is inconsistent in several parts. The manuscript should also be revised for a scientific paper format.</p></disp-quote><p>We appreciate the reviewer's comments and have taken them into consideration along with similar inquiries from Reviewer 1. Following the suggestions, we conducted a comparison of gene expression profiles between our hiPSC-derived microglia and those from fetal/adult brain microglia, as depicted in the updated Fig.2. Suppl. B, C and D; as well as in the Suppl. table 1 and table 2. The correlation analysis demonstrated that the hiPSC-derived microglia cells closely resemble fetal and adult brain microglia, significantly differing from monocytes and inflammatory monocytes. Additionally, we have revised the manuscript to adhere more closely to the conventional scientific format.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Specific suggestions for improvement:</p><p>- Regarding the characterization of human iPSC-derived microglia, P2RY12 is a general hematopoietic cell marker. One cannot judge the maturity of microglia only by P2RY12 expression (for example, line 261). The expression of more specific markers such as TMEM119 and PROS1 should be studied and discussed.</p></disp-quote><p>We are thankful for the reviewer's valuable feedback. In response:</p><p>We have removed the term &quot;mature&quot; and clarified that the hiPSC-derived microglia we studied are fully differentiated within single-type cell culture conditions.</p><p>We performed a comparative analysis of the gene expression profiles between our hiPSC-derived microglia and microglia from human brains, as illustrated in the updated Fig.2. Suppl. B, C and D. The results affirm that hiPSC-derived microglia closely resemble human fetal and adult microglia.</p><p>We noted that the expression of TMEM119 in hiPSC-derived microglia under in vitro single-type cell culture conditions is notably low, as shown in the below A. This suggests that the stimulatory factors in our single-type cell culture might not sufficiently induce TMEM119 expression in microglia. The necessity for a retinal environment or interaction with neuronal and/or other glial cells for TMEM119 expression mirrors the behavior of infiltrating peripheral monocytes in pathological conditions, which initially lack TMEM119 but later differentiate into microglial-like macrophages that express TMEM119, as reported by Ma et al. in Sci Rep (2017).</p><p>Additionally, our findings suggest that PROS1 is not uniquely characteristic of microglia but is expressed across a variety of cell types. Within our specific culture conditions, we noted a higher expression of PROS1 in microglial progenitor cells, as shown in Author response image 1B and C.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90695-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>- In Figure 2, Part E, the names of the genes or pathways in the figure are not clear, and are these genes the set that are the most differentially expressed between iPSCs-derived microglia and MPC? The analysis needs more explanation.</p></disp-quote><p>We regret any confusion caused by our previous explanation. To clarify, we compiled a list of microglia-enriched genes from the research conducted by Barres BA Lab (Bennett et al., Proc Natl Acad Sci U S A, 2016) and from our own RNA sequencing data of mouse retinal microglia, identifying a total of 130 genes predominantly expressed in microglia (Suppl. Table 3). We then applied this gene list to analyze our hiPSC-derived microglia RNA sequencing data, resulting in the identification of 71 microglia-specific genes. These 71 genes were subjected to Ingenuity Pathway Analysis (IPA) to visualize the signaling pathways involved. The details of these microglia genes can be found in the updated suppl. table 3.</p><disp-quote content-type="editor-comment"><p>- Lines 124 to 128 mention that high expression of Stat3, IL1b, and IL6 and their central role in pathway analysis emphasize the efficiency of the maturation protocol. Regarding the fact that Stat3, IL1b, and IL6 are contributors to proinflammatory pathways, it is not convincing that the high expression of these genes in iPSC-derived microglia demonstrates the efficiency of the maturation protocol, given that microglia are not stimulated.</p></disp-quote><p>Thanks for the comments! We added the sentences about the comparison results between hiPSC-derived microglia and human brain microglia. We have also replaced the “mature” with “functional.” The sentence reads, “Thus, our method of obtaining differentiated microglia is a reliable method to generate a large number of homogenous functional microglia cells.”</p><disp-quote content-type="editor-comment"><p>- Statistical analysis is missing for some graphs, for example, figures 1-3 and 5.</p></disp-quote><p>We appreciate the comments. We have added the statistical results in the revised version.</p><disp-quote content-type="editor-comment"><p>- The legend for Figure 3 needs to be rewritten. The graphs or applied assays should be explained in the legend, not the interpretation of the data.</p></disp-quote><p>The legend was rewritten.</p><disp-quote content-type="editor-comment"><p>- There is no Figure 3 in the supplement figures file.</p></disp-quote><p>We added Figure 3. Suppl.</p><disp-quote content-type="editor-comment"><p>- hTMEM119 staining in Figure 5, Part D, is mostly background. Please provide another image.</p></disp-quote><p>The images were unclear after on-line converting due to the low number of pixels. We replaced them with new hTMEM119 staining images in Figure 5D.</p><disp-quote content-type="editor-comment"><p>- In line 176, figure 5I has been forgotten to be mentioned.</p></disp-quote><p>Thank you very much! We added 5I.</p><disp-quote content-type="editor-comment"><p>- Lines 241 to 244 state that more than 50% of the AMD-associated genes are highly expressed in retinal microglia according to Fig. discussion suppl A &amp; B. It is not clear that the gene set that was used for analysis is from a healthy retinal microglia or AMD-related ones. Please explain precisely.</p></disp-quote><p>Thank you for your feedback. The gene list we referenced originates from a Genome-Wide Association Study (GWAS) that compared patients with Age-related Macular Degeneration (AMD) to healthy cohorts. We did not directly utilize this list in our experiments but referred to it to underscore the importance of microglia cells in the context of AMD.</p><disp-quote content-type="editor-comment"><p>Some of the English proofreading and manuscript format comments:</p><p>Line 805: Iba1 is written in lowercase. Is it human IBA1? It is not consistent with the way it is written in the text (in line 117, for example).</p></disp-quote><p>Thank you for pointing out the error. We reformed all Iba1 as “Iba1”. The Iba1 we used here are all from Wako (#019–19741), which labels both mouse and human microglial cells.</p><disp-quote content-type="editor-comment"><p>Line 814: microglia-enriched gene expression instead of microglia-enrich gene expression</p></disp-quote><p>Thank you! We changed it.</p><disp-quote content-type="editor-comment"><p>Line 345: Starting a sentence with lower case letter.</p></disp-quote><p>Thank you! We changed it.</p><disp-quote content-type="editor-comment"><p>Line 342: Myeloid lineage instead of myeloid cell linage.</p></disp-quote><p>Thank you! We changed it.</p><disp-quote content-type="editor-comment"><p>Line 815: What does FPKM stand for? The abbreviations should be explained.</p></disp-quote><p>The FPKM is the abbreviation of Fragments Per Kilobase of transcript per Million mapped reads. We added it in the text.</p><disp-quote content-type="editor-comment"><p>Line 309: The manuscript has occasionally referred to PLX-5622 without a minus. Please follow a uniform format.</p></disp-quote><p>We changed all “PLX5622” to “PLX-5622”.</p><disp-quote content-type="editor-comment"><p>Lines 327-331: should be rewritten.</p></disp-quote><p>The mentioned paragraph was rewritten.</p><disp-quote content-type="editor-comment"><p>Lines 335-340: should be rewritten.</p></disp-quote><p>The mentioned sentence was rewritten.</p><disp-quote content-type="editor-comment"><p>Line 135: qRT-PCR instead of QPCR,&quot; as it is also mentioned in the methods and material. The correction also applies to all the QPCRs in the text.</p></disp-quote><p>We changed “QPCR” with “qRT-PCR”</p><disp-quote content-type="editor-comment"><p>Figure 3: Graph B should be right side of graph A</p><p>Images description: It is better to have the images description in the left side of the image, for example, figure 5 part B, GL, IPL and OPL</p></disp-quote><p>Thanks for the suggestion. We changed the image organization as per the reviewer’s advice.</p><disp-quote content-type="editor-comment"><p>Lines 258 to 260 in the discussion have also been repeated with the same words in the introduction.</p></disp-quote><p>The mentioned paragraph was rewritten.</p><disp-quote content-type="editor-comment"><p>Lines 327-331 should be rewritten.</p></disp-quote><p>The mentioned paragraph was rewritten.</p><disp-quote content-type="editor-comment"><p>Lines 335-340 should be rewritten.</p></disp-quote><p>The mentioned paragraph was rewritten.</p></body></sub-article></article>